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1. Summary 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative condition characterized by 
behavioral changes and memory impairments, predominantly observed in the elderly 
population. As the most common form of dementia worldwide, AD has a large 
socioeconomic burden that is expected to grow in the next decades, given that no potent 
therapeutic strategy exists to treat the increasing population of aged individuals. The 
deposition of misfolded β-amyloid (Aβ) within extracellular senile plaques is a pathological 
hallmark of disease. The appearance of Aβ plaques has been identified as one of the earliest 
events in AD, and the prevailing amyloid cascade hypothesis suggests that the abnormal 
cleavage and misfolding of Aβ is the trigger of disease. The focus on misfolded Aβ as a 
central agent in AD has drawn parallels to the infectious prion protein and the protein-only 
hypothesis of disease transmission for prion disease. A number of studies have demonstrated 
that Aβ assembles into amyloid fibrils and that misfolded species can seed the aggregation of 
monomeric Aβ both in vitro and in vivo. Although the seeding properties of aggregated Aβ 
are robust, a more recent line of investigation aimed to characterize how variations in Aβ 
aggregate assembly influence the potency of seeding and also the progression of disease. 
 
In this doctoral dissertation, the structural features of amyloid plaque cores within a diverse 
cohort of 40 patients, with either sporadic or familial AD, were assessed using a unique class 
of conformation sensitive amyloid binding dyes referred to as luminescent conjugated 
oligothiophenes or LCOs. The fluorescence spectral signature of LCO stained plaque cores 
was strikingly different between familial AD and sporadic AD, and subtle differences were 
also identified between the typical and posterior cortical atrophy variants of sporadic AD. 
This demonstrates that the amyloid structure is distinct between AD subtypes, an observation 
not explained by Aβ biochemical features or clinical data. Surprisingly, within a single AD 
brain, multiple spectral signatures for amyloid were present and are referred to as clouds of 
conformational Aβ variants. The structural features of human AD-derived Aβ aggregates 
were also preserved upon transmission to human APP transgenic mice. The direct analysis of 
Aβ conformations within post-mortem human tissue provided insight into the spectrum of 
species present within a brain, but the presence of such Aβ variation at earlier stages of 
disease is unknown. 
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In a second study, the change in conformational and biological Aβ features with aging was 
studied in APP transgenic mouse models with either slow or rapid cerebral β-amyloidosis. 
Both histological and biochemical levels of Aβ increased with aging, but the ratio of specific 
Aβ species, namely Aβ42/40, surprisingly peaked at the early stage of plaque appearance in 
the two models. An in vivo bioassay was then used to show that different aged brain extracts 
had increasing seeding activities, or seeding dosages (SD50), that plateaued with advanced age 
when injected into a transgenic host. Interestingly, when seeding activity was normalized to 
the amount of Aβ within the extracts, a peak in specific activity became apparent at the age 
when Aβ deposition first appears and Aβ42/40 was highest. This study provides further 
evidence that treatment of AD should be initiated early, i.e. at the time point when these 
potent seeds are present and before a cascade of neurodegeneration can occur. 
 
Finally, in a third study, a novel methodology capable of investigating various native Aβ 
assemblies in the brain was described. Here, the use of agarose electrophoresis facilitated the 
separation of Aβ aggregation states by size, and demonstrated that transgenic mouse brain 
extracts harbor Aβ aggregates with a different size distribution than in vitro Aβ fibrils. 
Agarose fractions were collected and enzymatically digested to produce a liquid sample, 
which could be used for further analysis. Immunoprecipitation with an amyloid-
conformation-specific antibody confirmed that Aβ migrating with a high molecular weight 
had a preserved quaternary structure after the enrichment protocol. Further evidence that the 
structure was preserved was demonstrated when a high molecular weight fraction induced Aβ 
deposition when injected into transgenic mice. This novel tool provides the opportunity to 
screen potential therapeutic antibodies or compounds against native in vivo aggregates, while 
generating samples that can be further analyzed to determine the relationship between 
aggregate size and structure with biological features such as seeding activity. 
 
The original research within this dissertation has provided a significant contribution to the 
knowledge of Aβ structural features within AD, and the seeding properties over the course of 
disease. Additionally, the establishment of a new method for isolating in vivo seeds using 
agarose fractionation will allow for further basic investigations of these findings and aid in 
the development of novel therapeutics. Specifically targeting the earliest generated seeds 
within an AD subtype using immunotherapies could enhance the removal of pathogenic Aβ 
and provide a viable strategy to prevent AD. 
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2. Synopsis 
2.1 Overview of Alzheimer’s disease 
2.1.1 Demographics and pathophysiology 
 
The first characterization of AD occurred over 100 years ago by a physician for whom the 
disease was later named, Alois Alzheimer (Alzheimer 1907). This seminal description of the 
subject Auguste D. outlined the typical clinical presentation, which current AD patients 
share, namely, pronounced cognitive impairment and behavioral changes. The presentation 
by Alois Alzheimer of his work at a conference received little attention and was rather 
thought of as an unexceptional case of general age-related dementia. It was not until later that 
the importance of this description was fully appreciated. With further investigation, it was 
realized that AD was an affliction that classified the largest portion of patients with dementia. 
In the decades since, significant advancements have been made to better understand AD and 
more specifically, the molecular players and the subtleties that lead to divergent clinical 
presentation. 
 
At the moment, AD is the most common form of dementia and thus has a large 
socioeconomic burden. It is estimated that by 2030, more than 70 million people will be 
living with AD with a healthcare burden of over $2 trillion (USD) annually worldwide 
(World Alzheimer Report 2015). Although there are some recent studies to suggest that the 
incidence of dementia may be decreasing in developed nations, it is important to consider that 
as lesser-developed countries advance, the number of AD cases worldwide will increase in 
parallel with the number of aged individuals (Rocca et al. 2011; Satizabal et al. 2016). Such 
increases in global AD numbers underline that a persistent research effort is imperative to 
halting the progression of this disease. 
 
AD predominantly affects the elderly population, with advanced age being the strongest 
predictor of symptomology (Alzheimer’s Association 2014). Gross structural changes in the 
brain are visible in patients due to neurodegeneration in the neocortex and hippocampus 
which progresses to other brain areas at advanced stages of disease (Alzheimer’s Association 
2014). The cortical neuron tissue is also populated by deposits of proteins, which are now 
recognized as the pathological hallmarks of disease and part of the diagnostic criteria of AD 
(Serrano-Pozo et al. 2011; Dubois et al. 2016). Extracellular senile plaques consist 
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predominantly of the β-amyloid peptide (Aβ) (Alzheimer 1907; Alzheimer 1911; Divry et al. 
1927; Masters et al. 1985; Wong et al. 1985). The origin of the Aβ peptide was later tracked 
to the amyloid precursor protein (APP), as a natural cleavage product of this larger 
transmembrane protein (Haass et al. 1992). The second protein pathology that is also part of 
the diagnostic criteria are intracellular tangles or neurofibrillary tangles (NFTs) which are 
composed of the microtubule-binding protein, tau (Goedert et al. 1988; Kondo et al. 1988; 
Wischik et al. 1988). It is worth noting that the AD brain is also characterized by an 
inflammatory reaction mediated by activated astrocytes and microglia (Heneka et al. 2015). 
 
The relationship between the hallmark Aβ and tau pathologies and the progression of disease 
has been strengthened using biomarkers and diagnostic imaging strategies. Progressive 
deposition of Aβ in the brain has been investigated using the radioactive amyloid β-binding 
molecule, Pittsburgh compound B (PiB) paired with positron emission tomography (PET) 
(Klunk et al. 2004). Similar radioactive amyloid binding dyes with a longer half-life have 
also been used in recent years (Clark et al. 2012; Wolk et al. 2012). Through PET imaging 
the longitudinal accumulation of Aβ deposits in brain tissue has been elucidated and confirms 
the cross-sectional histology stages in post-mortem brain tissue, however, the sensitivity of 
PET is not optimized for the detection of the earliest Aβ deposits (Thal et al. 2002; Thal et al. 
2015). Additionally, using sensitive immunoassays against Aβ, it has been determined that a 
low concentration of the 42 amino acid long variant of Aβ in the cerebrospinal fluid (CSF) is 
a strong predictor of cognitive decline (Shaw et al. 2009; van Harten et al. 2013; Dubois et 
al. 2016). Astonishingly, the changes in CSF Aβ content occur decades before the presence 
of cognitive symptoms within a patient (Bateman et al. 2012; Buchhave et al. 2012; Dubois 
et al. 2016). This emphasizes that AD is not only a geriatric disease but also starts early and 
progresses slowly when considering brain physiology. Similar perturbations in tau 
physiology can be tracked in the CSF during the progression of AD and, although not as 
early, CSF-tau levels increase prior to the onset of cognitive decline (Fagan et al. 2007; 
Bateman et al. 2012; Buchhave et al. 2012; Dubois et al. 2016). There are a number of 
promising imaging molecules being developed for detecting tau pathology, such as 
flortaucipir and T807, similar to the Aβ radioligands mentioned above, however, their 
specificity is not yet satisfactory (Brier et al. 2016; Pontecorvo et al. 2017; Saint-Aubert et 
al. 2017). Together, these analytical methods not only strengthen the link of these proteins to 
the progression of AD but also give a context for the temporal occurrence of brain 
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disturbances. This is important for determining whether a patient with cognitive impairment 
has AD prior to confirmation at autopsy and it also provides a way to track the efficacy of 
therapeutic agents in clinical trials (Jack et al. 2013; Dubois et al. 2016; McDade and 
Bateman 2017).  
 
2.1.2 The amyloid precursor protein and β-amyloid 
 
APP is a single pass type I membrane protein and, although it is better known for its presence 
in the brain, it is expressed throughout the body (Goldgaber et al. 1987; Kang et al. 1987; 
Tanzi et al. 1987; Muller et al. 2017). In the brain, the 695 amino acid long splice variant is 
predominantly expressed, while longer variants (751 and 770 mostly) are found in non-
neuronal tissue (Muller et al. 2017). Research into the function of APP as a membrane 
protein has yielded a number of diverse roles (Muller et al. 2017). Specifically, there has 
been evidence to show that APP is involved in cell adhesion and neurite outgrowth through 
interactions between the extracellular portion and extracellular matrix proteins (Soba et al. 
2005; Olsen et al. 2014; Muller et al. 2017). However, when the APP protein is deleted in 
mice, there are no severe phenotypes, suggesting that redundant functions by the APP family 
of proteins are compensated for by APP loss (Zheng et al. 1995; Muller et al. 2017). 
 
Cleavage Pathways 
The APP protein is not only present as a full-length membrane protein but is also cleaved by 
secretases generating multiple peptide fragments. The most common pathway is referred to as 
the non-amyloidogenic pathway where the initial cleavage is made by α-secretase (α-
secretase disintegrin and metalloproteinase domain-containing protein 10, ADAM10) 
yielding a soluble extracellular fragment of APP (sAPP-α) and the membrane bound C-
terminal C83 fragment (Figure 1; Kuhn  et al. 2010). This fragment is then further processed 
by the γ-secretase complex, producing the APP intracellular domain (AICD) and p3 peptides 
(Takami et al. 2009). The sAPP-α fragment is important for long-term potentiation (LTP) 
and even rescues some of the subtle deficits seen in APP knock-out mice (Ring et al. 2007; 
Taylor et al. 2008). AICD has been linked to transcriptional regulation, while the function of 
p3 has not been clearly identified (Cao and Sudhof 2001; Gao and Pimplikar 2001; Muller et 
al. 2017). Thus, it seems that not only full-length APP, but also the fragments generated by 
cleavage have a role in brain physiology. 
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APP can alternatively be processed through the amyloidogenic pathway, which is associated 
with the disease state in AD (Figure 1). In contrast to the above pathways, the initial 
cleavage of APP is carried out by the β-secretase, β-site APP cleavage enzyme 1 (BACE1) 
which is the BACE isoform expressed in the brain (Vassar et al. 2014). Cleavage of APP by 
BACE1 generates a shorter soluble fragment (sAPP-β) than the non-amyloidogenic pathway 
(Vassar et al. 2014). The remaining C-terminal fragment, C99, is then cleaved by the γ-
secretase complex and, similar to the non-amyloidogenic pathway, generates the AICD 
peptide but releases the disease-associated Aβ peptide as well (De Strooper et al. 1998; 
Wolfe et al. 1999). The Aβ peptide has been extensively studied to determine its 
amyloidogenic properties and their contribution to disease. 
 
More recently, another cleavage pathway has been identified that generates a peptide with 
neurotoxic features and is referred to as the η-secretase pathway (Figure 1; Willem et al. 
2015). In this pathway, η-secretase, suggested to be the matrix metalloprotease MT5-MMP, 
cleaves the APP protein releasing a soluble fragment (sAPP-η) while subsequent cleavage by 
either α- or β-secretase generates the Aη peptide (Aη-α or Aη-β, respectively) (Willem et al. 
2015). This small, extracellularly shed fragment, Aη-α, has synapse impairing properties 
both in cell culture and in vivo (Willem et al. 2015). Surprisingly, it was also found that 
inhibition of β-secretase causes an increase in Aη-α, suggesting that such therapeutic 
interventions can have unintended and potentially detrimental effects on patient health 
through the generation of neurotoxic peptides (Willem et al. 2015). The elucidation of the η-
secretase pathway has added another dimension to APP cleavage and the fragments generated 
by physiological processing. 
 
Mechanism of γ-secretase cleavage 
The generation of multiple different amino acid length species of Aβ is largely controlled by 
the γ-secretase complex mentioned above, which is a membrane bound secretase capable of 
intramembranous cleavage of proteins (Voytyuk et al. 2017). This phenomenon was first 
discovered with the γ-secretase complex but similar intramembranous cleavage has since 
been identified for other proteins (De Strooper et al. 1998; Wolfe et al. 1999; Voytyuk et al. 
2017). The γ-secretase multi-protein complex comprises nicastrin, anterior pharynx-
defective-1, presenilin enhancer 2 and presenilin-1 or 2 (PSEN1 or 2). Either PSEN1 or 2 is 
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the catalytic subunit of γ-secretase responsible for cleaving the APP protein, and, as 
mentioned above, liberates Aβ at the carboxy-terminus from the membrane associated C99 
fragment (De Strooper et al. 1998; Wolfe et al. 1999). Recently, a study demonstrated that 
PSEN1 and PSEN2 have distinct subcellular locations, with PSEN1 being found throughout 
the cell and PSEN2 localizing to the endosomes (Sannerud et al. 2016). This leads to an 
intracellular pool of longer Aβ peptides when APP is processed by PSEN2, demonstrating 
that while both active subunits cleave the C-terminal fragment, the subcellular location 
determines their effect on APP physiology (Sannerud et al. 2016). In general, it is known that 
Aβ exists as multiple different length variants at both termini of the peptide, including N-
terminal pyroglutamation at position 3 or 11 within the brain (Mori et al. 1992; Naslund et al. 
1994; Saido et al. 1996; Portelius et al. 2010). Recently, the precise mechanism for the 
generation of different C-terminal variants of Aβ was described (Takami et al. 2009; Bolduc 
et al. 2016). It was shown that γ-secretase cleaves the peptide in a sequential tripeptide 
fashion (Bolduc et al. 2016). In other words, C99 is cut by PSEN1 and subsequent cleavage 
occurs three amino acids closer to the N-terminus with this process occurring multiple times 
(Bolduc et al. 2016). This process also validated previous work showing that there are two 
pathways of Aβ generation, one generating Aβ ending in amino acid 40 (Aβ40) (Aβ49-->46-
->43-->40) and another generating Aβ ending in amino acid 42 (Aβ42) (Aβ48-->45-->42--
>38) (Figure 1; Takami et al. 2009; Bolduc et al. 2016). Aβ40 and Aβ42 are the two 
peptide-variants most abundant in the AD brain and have been recently suggested to prefer 
different sites of deposition, with Aβ40 in the vasculature as cerebral amyloid angiopathy and 
Aβ42 in parenchymal plaques (Kakuda et al. 2017). Aβ42 is the more aggregation prone 
variant and, consequently, has been a focus of studies on the pathogenicity of Aβ and the 
progression of disease through its use as a biomarker (Jarrett et al. 1993; Haass and Selkoe 
2007; Shaw et al. 2009; Bateman et al. 2012). 
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Figure 1. APP cleavage pathways and the mechanism of γ-secretase tripeptide cleavage. 
The non-amyloidogenic pathway proceeds with α-secretase (ADAM10) cleavage of APP 
releasing sAPPα, followed by γ-secretase cleavage of C83 to produce AICD and p3. 
Conversely, the η-cleavage pathway has an initial cleavage of APP by η-secretase (MT5-
MMP) that releases sAPPη. The remaining CTFη peptide (approximate peptide length of 190 
aa) can be cleaved by either β-secretase (BACE1) or α-secretase that produces Aη-β or the 
neurotoxic Aη-α peptide, respectively. The amyloidogenic pathway proceeds with β-
secretase cleavage of APP (releasing sAPPβ) then γ-secretase cleavage of C99. The γ-
secretase complex processes C99 with an initial ε-cut (Aβ48 or Aβ49) and then sequential 
carboxypeptidase cleavage (γ) in three peptide intervals (tripeptide cleavage). This releases 
the disease associated Aβ peptide, where two separate pathways generate Aβ40 and Aβ42. 
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Genetics of familial AD 
The APP protein and its cleavage has also been linked to AD through dominantly inherited 
mutations in APP and the PSEN1&2 proteins that lead to the familial form of AD (fAD) 
(Goate et al. 1991; Sherrington et al. 1995; Karch and Goate 2015). This class of AD is not 
common and only explains approximately 1% of all positively identified cases (Alzheimer’s 
Association 2014). In general, all of these mutations have been implicated in altering the 
processing of APP by the secretases described above (Voytyuk et al. 2017). A number of 
mutations in APP itself cluster around the two cleavage sites in the amyloidogenic pathway 
for β-secretase and γ-secretase (Goate et al. 1991; Murrell et al. 1991; Mullan et al. 1992). 
This has been suggested as causing an important alteration in APP cleavage, leading to an 
increased production of longer isoforms of Aβ (Szaruga et al. 2017; Voytyuk et al. 2017). As 
described above, an increase in Aβ42 has been linked to disease given its aggregation prone 
and neurotoxic nature (Jarrett et al. 1993; Haass and Selkoe 2007). Additionally, mutations in 
the catalytic γ-secretase protein, PSEN1, generally have increased production of Aβ species 
in cell assays, and more specifically the longer forms of Aβ, including Aβ42 (Szaruga et al. 
2015). Recently, a more mechanistic understanding of the effect of mutations in the PSEN 
proteins has been realized. Specifically, the efficiency of cleavage at the γ-secretase site in 
APP is decreased in a number of PSEN mutations (Szaruga et al. 2015; Szaruga et al. 2017). 
This has implications given the tripeptide cleavage mechanism of γ-secretase, whereby less 
efficient cutting will lead to a premature release of the substrate (C99) from the substrate-
enzyme complex (C99-PSEN) and consequently a longer Aβ species (Bolduc et al. 2015; 
Szaruga et al. 2017). This was similarly shown for APP mutations, where longer Aβ 
fragments were released by wildtype PSEN1 (Szaruga et al. 2017). This demonstrates the 
precise mechanism behind many mutations causing fAD and how changes in APP processing 
are linked to disease. 
 
An interesting parallel to fAD mutations is the increased risk of AD in human subjects with 
Down’s syndrome. This genetic disorder is caused by trisomy of chromosome 21, which 
leads to distinctive cranial development and mental retardation (Rovelet-Lecrux et al. 2006). 
The APP gene is located on chromosome 21 and the overexpression of APP protein leads to 
an early presence of Aβ plaque pathology (Rovelet-Lecrux et al. 2006). Consequently, these 
subjects will commonly develop full-blown AD if an advanced age is reached. As such, both 
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fAD and Down’s syndrome demonstrate that changes in Aβ physiology within the brain are 
at the root of AD. 
 
Sporadic AD and risk factors 
The other and most common form of AD is known as sporadic AD (sAD) and, as the name 
suggests, does not have a defined cause. It is considered to be a multi-factorial form of AD 
with a complex etiology leading to neurodegeneration. Despite the different origin, sAD is 
still quite similar to fAD in terms of the presence of senile plaques and NFT at autopsy and 
their disease progression (Day et al. 2016). Genome-wide association studies (GWAS) have 
provided a wealth of information about genetic risk factors for developing AD (Karch and 
Goate 2015). There are a small number of genes that confer a moderate risk for AD, while at 
the same time have a moderate abundance in the human population (Karch and Goate 2015). 
Both TREM2 and ApoE4 are such gene products and have been extensively studied to 
determine their involvement in AD (Karch and Goate 2015). Physiologically, the ApoE 
proteins are involved in cholesterol metabolism through binding to low-density and very low-
density lipoproteins (LDL and vLDL, respectively) (Mahley et al. 1988). From a disease 
perspective, the ApoE proteins show an affinity for Aβ binding which has been linked to Aβ 
clearance from the brain (Kim et al. 2009). A recent study further solidified this link using a 
novel bioengineered blood vessel model (Robert et al. 2017). The ApoE4 variant has also 
been suggested to facilitate Aβ aggregation and production (Hashimoto et al. 2012; Huang et 
al. 2016). These findings support recent work showing that ApoE4 plays an important role in 
enhancing the onset of Aβ plaque deposition (Huynh et al. 2017; Liu et al. 2017). When 
considering the TREM2 protein there is also a connection to Aβ but instead through 
microglia, the phagocytic immune cells of the brain. Microglia have an activated morphology 
in AD and cluster around Aβ plaques, while having the ability to engulf and degrade Aβ 
(Bard et al. 2000; Bolmont et al. 2008; Heneka et al. 2015). TREM2 expression on microglia 
is crucial for these behaviors and consequently limits neuritic injury caused by plaques 
(Kleinberger et al. 2014; Wang et al. 2016). Mutations in TREM2 linked to AD also confer a 
reduced phagocytic capacity of microglia (Schlepckow et al. 2017). Recent studies have even 
implicated TREM2 in mediating the removal of Aβ after immunotherapy (Xiang et al. 2016). 
Interestingly, a link between TREM2 and ApoE in cerebral β-amyloidosis has been identified 
through the transcriptional signature of microglia and a mechanism where a TREM2-ApoE 
complex facilitates Aβ phagocytosis by microglia (Yeh et al. 2016; Krasemann et al. 2017). 
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As is apparent, the clearance of Aβ from the brain is important for normal brain physiology 
and as such has been hypothesized as a general cause of sAD (Wang et al. 2017). There are a 
number of degradation pathways that include proteolytic degradation both intracellularly in 
glial cells of the brain or extracellularly (Heneka et al. 2015; Tarasoff-Conway et al. 2015). 
Substantial clearance of the Aβ peptide also occurs through bulk flow of the interstitial fluid 
(Tarasoff-Conway et al. 2015; Wang et al. 2017). The Aβ within these fluids can then cross 
to the blood circulation through receptor mediated pathways or absorption (Tarasoff-Conway 
et al. 2015; Wang et al. 2017). Once in the periphery, degradation can occur in peripheral 
immune cells or within the hepatocytes of the liver (Tarasoff-Conway et al. 2015; Wang et 
al. 2017). The risks of sAD as briefly shown here, outline that a number of these factors can 
be directly linked to the Aβ peptide, similar to fAD. 
 
Amyloid Cascade Hypothesis 
One of the most widely accepted mechanistic frameworks for explaining AD pathogenesis is 
the amyloid cascade hypothesis and is based off the central role that the Aβ peptide has in the 
disease, as indicated above (Selkoe and Hardy 2016). In this framework that applies to both 
fAD and sAD, increased levels of Aβ in the brain lead to aggregation and the formation of 
oligomers (Selkoe and Hardy 2016). These Aβ species eventually deposit in the parenchyma 
leading to an inflammatory response and changes in synapse biology, such as an increased 
excitability (Selkoe and Hardy 2016). In later stages of the cascade, hyperphosphorylated tau 
mislocalizes in the soma of neurons (Selkoe and Hardy 2016). Finally, this tau alteration 
causes NFT formation and neuronal death occurs, leading to the clinical presentation of 
cognitive decline in patients (Selkoe and Hardy 2016). Some of the strongest support for this 
hypothesis lies in the dominantly inherited genetic data, where only mutations affecting the 
APP protein and its processing are guaranteed to cause AD (Karch and Goate 2015; Selkoe 
and Hardy 2016). Furthermore, a protective mutation in APP, A673T, identified in an 
Icelandic population, lends strong support to the amyloid cascade hypothesis (Jonsson et al. 
2012). Interestingly, although tau is a pathological hallmark of AD and correlates strongly 
with cognitive decline, there are no tau mutations linked to AD, suggesting that changes in 
Aβ are a crucial event in AD (Karch and Goate 2015; Polanco et al. 2018). As outlined in the 
amyloid cascade hypothesis it seems likely that the temporal occurrence of Aβ and then tau 
may also explain the genetic importance of Aβ in AD (Selkoe and Hardy 2016). Although it 
is proposed as a rather linear model of disease progression, there is discussion about the 
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precise order of these steps and how each of these interacts with each other (De Strooper and 
Karran 2016). It seems likely, that after an initial “hit” caused by Aβ misfolding, changes in 
tau and neuroinflammation will interact with Aβ and each other on multiple levels to cause 
neuronal death and a feed-forward mechanism. Some alternative hypotheses exist for AD, 
such as the cholinergic hypothesis and cardiovascular hypothesis. The cholinergic hypothesis 
focuses on the fact that cholinergic neurons in the basal forebrain degenerate during AD 
while the cardiovascular hypothesis views AD as a disease centered around impaired 
circulation and vascular abnormalities (Francis et al. 1999; de la Torre 2010). Although these 
and other hypotheses do focus on an AD related physiological abnormality, they do not have 
the strength of the amyloid cascade hypothesis in explaining the molecular mechanism 
leading to brain pathology and dysfunction. 
 
Experimental models of AD 
The occurrence of AD is a uniquely human affliction with no other species displaying the full 
pathologies and typical AD cognitive deficits (Walker and Jucker 2017). Even in non-human 
primates that reach significantly advanced age there is not the same pairing of Aβ and tau 
protein deposits in relevant brain regions (Walker and Jucker 2017). This is an intriguing 
phenomenon that begs the question of what makes humans so vulnerable to this devastating 
disease. Research into the mechanisms of AD has aimed at overcoming this hurdle using 
transgenic mouse models expressing human forms of APP and tau (Gotz and Ittner 2008). A 
number of the models for AD pathology have focused on a single pathology, namely Aβ or 
tau. It must be noted that the transgenic mice developing tau pathology as NFT contain tau 
mutations that are not associated with AD, questioning the relevance of these models to AD 
specifically (Gotz and Ittner 2008). However, a number of different mouse models have been 
developed that demonstrate robust Aβ plaque pathology. Two well-studied models of 
cerebral β-amyloidosis are the APP23 and APPPS1 mouse lines (Sturchler-Pierrat et al. 
1997; Radde et al. 2006). Each transgenic model overexpresses the human APP protein 
(APP23 7-fold; APPPS1 3-fold) containing the Swedish double mutation (KM670/671NL) 
under the control of the Thy1 neuronal promoter (Sturchler-Pierrat et al. 1997; Radde et al. 
2006). In addition, the APPPS1 transgenic line expresses mutated human PSEN1 (L166P) 
under the same Thy1 promoter (Radde et al. 2006). The APP23 model demonstrates a late-
onset of pathology at approximately 6 months of age with larger parenchymal deposits and 
cerebral amyloid angiopathy (Sturchler-Pierrat et al. 1997). Alternatively, the APPPS1 model 
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has an early onset of 1.5 months and, with aging, plaques are comparatively smaller and more 
numerous than in APP23 (Radde et al. 2006). These transgenic models, as well as a number 
of others have been used to learn more about the exclusive effects of Aβ on the neuronal 
environment and how immune cells like microglia and astrocytes react to these pathologies 
(Gotz and Ittner 2008). 
 
Models of cerebral β-amyloidosis are powerful tools for investigating the deposition of Aβ in 
vivo and the structure of amyloids in tissue, but it is worth noting some of the limitations 
when investigating physiological effects of Aβ pathology. For example, a number of these 
transgenic mice do not have significant neuronal loss (Gotz and Ittner 2008; Sasaguri et al. 
2017). Furthermore, most of these models overexpress a human protein that is under the 
control of a non-endogenous promoter (Sturchler-Pierrat et al. 1997; Radde et al. 2006; Gotz 
and Ittner 2008; Saito et al. 2014; Sasaguri et al. 2017). This produces an extra-physiological 
situation where it can be difficult to distinguish between effects caused directly by the 
intended transgenic alteration and the unintended alterations caused by disruptions to the host 
genome during integration or changes to the cellular physiology when a foreign protein is 
massively produced (Saito et al. 2014; Saito et al. 2016). Recently a novel model of β-
amyloidosis was developed using a knock-in strategy (Saito et al. 2014). With this strategy, 
Saito and colleagues (2014) were able to produce transgenic mice expressing humanized APP 
at physiological levels and under the control of the endogenous promoter. The study took 
advantage of different fAD mutations, including the previously mentioned Swedish mutation 
(KM670/671NL) and the Arctic (E693G) and Iberian (I716F) mutations in APP (Saito et al. 
2014). From a pathology perspective, these transgenic mice harbor Aβ deposits with 
associated inflammatory reaction of microglia and astrocytes, demonstrating that these mice 
can also be used as models of cerebral β-amyloidosis (Saito et al. 2014). 
 
Given that AD is a dual pathology disease without any associated dominantly inherited tau 
mutations, it is important to consider the best strategies to model the full spectrum of AD 
pathology in vivo. A recent study showed that tau pathology could be induced in wild-type 
mice when intracerebrally inoculated with insoluble tau extracted from AD brains (Guo et al. 
2016). Tau pathology was shown to spread through functionally connected neuronal 
networks, providing further support that this model mirrored physiological phenomenon 
identified in AD (Jucker and Walker 2013; Brettschneider et al. 2015; Guo et al. 2016). As 
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an extension of this novel model for AD-relevant tau pathology, a subsequent study paired 
the introduction of exogenous AD tau with different models of cerebral β-amyloidosis to 
produce a compelling AD model (He et al. 2017). The study determined that the presence of 
Aβ plaques resulted in pathological tau in dystrophic neurites initially but later as 
neurofibrillary tangles and neuropil threads in distal brain areas (He et al. 2017). Another 
recent study was able to demonstrate AD pathology in vivo by injecting neurons derived from 
human stem cells into the brain of APP transgenic mice, resulting in tau 
hyperphosphorylation and death of human neurons (Espuny-Camacho et al. 2017). The 
further development of AD models will advance our understanding of neurodegeneration in 
AD and the molecular mechanisms driving disease. 
 
2.1.3 The protein-only hypothesis: a unifying concept of disease 
 
The protein-only hypothesis was first proposed for a perplexing set of disorders called prion 
diseases that defied explanation for years (Prusiner 1982). Prion diseases are a class of severe 
neurodegenerative maladies, first identified in sheep with scrapie, a condition named after the 
excessive scratching phenotype in these animals (Stockman 1913). A number of other species 
are susceptible to prion diseases or transmissible spongiform encephalopathies (TSE), as they 
are also known (Collinge 2001). One of the most famous forms of prion disease is that 
affecting cattle, known as bovine spongiform encephalopathy (BSE) or, more colloquially, 
mad cow disease (Wilesmith et al. 1988). Cattle suffering from the disease present with 
severe neurological symptoms including abnormal gait, exaggerated motor reactions and in 
the latest stages an inability to stand (Wilesmith et al. 1988). From a pathology standpoint, 
the brain in TSE-infected organisms has a spongy appearance under the microscope due to 
massive neuronal death caused by the misfolded prion protein, PrPTSE, which deposits in the 
brain (Beck and Daniels 1987). This PrPTSE agent is derived from misfolding of the 
physiological, membrane-associated cellular form of the prion protein termed PrPC (Borchelt 
et al. 1990; Caughey and Raymond 1991). 
 
Prion diseases have also been identified in the human population and can have a number of 
origins. The most common form of prion disease is sporadic Creutzfeldt-Jakob Disease 
(sCJD) and does not have a defined single-factor cause but genetic risk factors have been 
identified (Palmer et al. 1991; Collinge 2001). There are rare genetic forms of prion disease 
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such as Gerstmann-Straeussler-Scheinker syndrome, which are caused by mutations in the 
PrPC encoding gene, PRNP (Hsiao et al. 1989). Additionally, there are forms of CJD that are 
linked to an exogenous introduction or infection with the PrPTSE agent (Collinge 2001). These 
are referred to as iatrogenic CJD (iCJD), caused by an exposure to PrPTSE-contaminated 
medical instruments, and variant CJD (vCJD), which is linked to consumption of beef 
products tainted with PrPTSE (Collinge et al. 1991; Collinge et al. 1996; Thomas et al. 2013). 
Kuru is another unique example of prion disease similar to vCJD caused by ritualistic 
cannibalism in the tribal Fore people of Papa New Guinea (Klatzo et al. 1959; Gajdusek et al. 
1966; Alpers 1987). These last three forms of CJD are central to the controversial history of 
prion diseases as being infectious but not caused by a classic virus or microorganism.  
 
Initially, prion diseases were thought to be caused by a slow virus, which led to severe 
neurodegeneration without a correspondingly severe inflammatory response (Gajdusek 
1977). Purification of the infectious agent proved challenging for a number of years and 
puzzled researchers because infectivity was not easily biochemically fractionated (Prusiner 
1982; Meyer et al. 1986). Additionally, foreign genetic material was never consistently 
identified (Alper et al. 1966; Alper et al. 1967; Prusiner 1982). Decades of rigorous 
experimentation by numerous groups led to the delineation of the protein-only hypothesis, 
positing that the infectious unit was devoid of nucleic acid and was a misfolded protein 
(Griffith 1967; Prusiner 1982). Although quite controversial at the time, this hypothesis has 
been further supported by research in recent years. One of the most important supports of this 
hypothesis was the generation of infectious PrPTSE from defined synthetic components 
(Legname et al. 2004; Deleault et al. 2007; Colby et al. 2009; Wang et al. 2010). This 
avoided any confounding factors when purifying the infectious agent from brain material 
where multiple different molecules are also purified. The exceptional stability of PrPTSE to 
physicochemical treatments like heat and fixation with formaldehyde was another factor that 
provided evidence that a bacterial or viral agent was not the culprit for prion disease (Brown 
et al. 1990; Zobeley et al.  1999). This recalcitrant phenotype is derived from the structural 
change that occurs during the transition from α-helical PrPC to the β-sheet enriched PrPTSE 
form. The PrPTSE agent has long been known to contain an enriched β-sheet structure and a 
recent study provided a more detailed view of an organized PrPTSE amyloid fibril (Bolton et 
al. 1982; Vazquez-Fernandez et al. 2016). Amyloid is a general quaternary structural motif 
defined by the ordered stacking of β-sheet segments that extend as an elongated fibril 
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(Eisenberg and Jucker 2012). Biophysically, this leads to a distinctive x-ray diffraction 
pattern when the beam is directed perpendicular to the fibril axis with a signal at 4.7Å and 
10Å (Eisenberg and Jucker 2012). The mechanism behind the infectious nature of PrPTSE is 
hypothesized as the ability of PrPTSE to induce PrPC misfolding (Borchelt et al. 1990; Caughey 
and Raymond 1991). Although the experimental proof of this specific misfolding event at the 
molecular level is still lacking, experiments using transgenic mice devoid of PrPC 
demonstrated that these animals are completely resistant to prion disease, emphasizing the 
key role of PrPC as a substrate (Bueler et al. 1993). 
 
Expanding prion concepts to neurodegenerative disease 
Although the protein-only hypothesis of prion diseases was controversial at its inception, this 
new concept for a disease-causing agent has gained popularity for other diseases where 
protein pathologies occur (Prusiner 2013; Walker and Jucker 2015; Collinge 2016; 
Rasmussen et al. 2017a). Indeed, many neurodegenerative diseases characterized by deposits 
of misfolded proteins like AD are being investigated for prion-like qualities (Walker and 
Jucker 2015). A number of studies working with autopsy tissue from individuals of varying 
age and disease status (healthy to severe disease) have facilitated models for staging 
neurodegenerative diseases based on the location of protein deposits (Brettscheider et al. 
2015). Pathologies in a number of diseases were determined to spread in a stereotypical 
manner, rather than appearing randomly, suggesting that a common mechanism, similar to 
the prion model of induced misfolding could exist (Jucker and Walker 2013; Brettschneider 
et al. 2015). 
 
When specifically considering Aβ, there have been quite some parallels drawn to the protein-
only hypothesis of PrPTSE that have resulted in a prion-like definition (Rasmussen et al. 
2017a). In the case of AD, cross-sectional human studies have demonstrated Aβ pathology 
spreading, which has led to a staging rubric along with tau pathology, but investigations in 
transgenic mice have more clearly demonstrated that pathology spreads through the brain 
along functionally connected networks (Clavaguera et al. 2009; Nath et al. 2012; Domert et 
al. 2014; Brettschneider et al. 2015; Calafate et al. 2015; Ye et al. 2015). Extending the 
prion-like moniker even further, Aβ has well documented amyloid tendencies and traditional 
staining methods for Aβ plaques include the amyloid specific dye, Congo Red (Divry et al. 
1927). However, it is worth mentioning that both PrPTSE and Aβ can form aggregated species 
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that are not in an ordered amyloid assembly but are still disease associated (Langer et al. 
2011; Philipson et al. 2012; Alibhai et al 2016; Rasmussen et al. 2017a). Aggregated Aβ is 
also extremely stable when exposed to proteases, fixatives, heat and denaturants, which 
parallels the PrPTSE agent (Meyer-Luehamann et al. 2006; Langer et al. 2011; Fritschi et al. 
2014b; Watts et al. 2014). 
 
The parallels drawn between AD and prion diseases spawning the prion-like definition has 
provided an invaluable road map for investigating molecular features of neurodegeneration 
(Walker and Jucker 2015; Rasmussen et al. 2017a). Using these principles, the role of Aβ in 
initiating disease and influencing phenotypic diversity has been advanced in recent studies to 
further validate targeting this misfolded protein for the development of therapeutic 
interventions. 
 
2.2 Heterogeneity of β-amyloid aggregates in Alzheimer’s disease 
2.2.1 Fibrillar β-amyloid structures and deposits 
 
The assembly of proteins into fibrillar amyloid aggregates is a well-defined phenomenon that 
occurs both in health and disease for multiple proteins but this quaternary structural motif can 
have varied characteristics (Riek and Eisenberg 2016). The β-sheet rich structures are 
typically arranged into extended fibrils at later stages of aggregation and can be classified 
based on the orientation of β-sheets (Tycko 2015; Riek and Eisenberg 2016). Namely, β-
sheets can be oriented in a parallel, anti-parallel or β-hairpin anti-parallel fashion and in all of 
these cases, the side groups of the β-sheet interdigitate and form a stable steric zipper (Figure 
2; Eisenberg and Jucker 2012; Tycko 2015). The Aβ peptide is capable of both parallel and 
anti-parallel orientations in vitro and in vivo (Qiang et al. 2012; Lu et al. 2013; Xu et al. 
2016). At the mesoscopic level, Aβ fibrils also vary based on their width, crossover rate and 
fibril mass per length, which can be distinguished by electron microscopy (Petkova et al. 
2005). These experiments largely rely on in vitro fibrillization of Aβ, where different 
conditions of fibril growth, like agitation and salt concentration, lead to different fibril 
characteristics (Qiang et al. 2012; Tycko et al. 2015;). Interestingly, it has been shown for a 
different protein (β-endorphin) that amyloid fibrils can have distinct mesoscopic properties, 
like the presence of crossovers while having the same atomic structure (Seuring et al. 2017). 
However, these subtle differences in Aβ fibril structure within a sample provide a hurdle to 
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gaining structural information from a fibril sample, as homogeneity is required for most 
structural biology techniques (Meier et al. 2017). 
 
 
Figure 2. Various orientations of β-sheet organization within a fibril. A peptide with two β-
sheet segments can organize as parallel, anti-parallel or β-hairpin anti-parallel in an amyloid 
fibril, which is determined by the stacking of β-sheets and the direction of adjacent β-sheets 
along the fibril axis. 
 
Aβ fibril structure 
The detailed structure of Aβ in pathogenic aggregates is a central focus of AD research in 
order to better understand the complexity of these pathologies. However, an accurate 
elucidation of Aβ structural information is hindered by the insoluble nature of the aggregated 
protein complexes. Therefore, methods have been developed in order to gain high-resolution 
information from amyloid fibrils. Solid-state nuclear magnetic resonance (ssNMR) is one of 
these methods, where detailed information can be gained about the structure of amyloids 
through the interaction of carbon and nitrogen nuclei (Meier et al. 2017). Additionally, 
scanning electron microscopy (SEM) and the more recent method cryo-electron microscopy 
(cryo-EM) have been used to determine the structure of Aβ using visual information obtained 
from an electron beam (Schmidt et al. 2009; Schmidt et al. 2015; Gremer et al. 2017). A 
significant problem with determining the structure of Aβ is that fibrils need to have a high 
concentration but also need to be of suitable purity and homogeneity. Therefore, the methods 
for obtaining high-resolution information rely either on purely in vitro made fibrils or in vitro 
amplified brain derived Aβ. In recent years, the structure of in vitro Aβ40 was shown with 
SEM to be constructed from two dimer protofilaments, with the C-terminus being involved in 
the fibril core and the N-terminus having a less defined structure (Schmidt et al. 2009) 
Conversely, in the same study the structure of an in vitro Aβ42 fibril contained only a single 
dimer protofilament but the C-terminus also populated the fibril core (Schmidt et al. 2009). 
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In a subsequent study using cryo-EM, Aβ42 again showed a single dimer protofilament unit, 
however there was an extended interface between dimers in the fibril core due to a kinked C-
terminus (Schmidt et al. 2015). In all of these cases the Aβ peptide is oriented as a “U” shape 
with two β-sheet segments adjacent to each other. Other structures of in vitro Aβ42 have 
suggested that the peptide has an “S” shape with three β-sheets in a single peptide and a 
single dimer protofilament in the fibril (Xiao et al. 2015; Walti et al. 2016; Gremer et al. 
2017). In two of these structures, the use of ssNMR revealed that the N-terminus was not 
involved in the fibril core similar to previous studies (Xiao et al. 2015; Walti et al. 2016). 
Surprisingly, one structure of in vitro Aβ42 using both cryo-EM and ssNMR has suggested 
that the entire peptide length is involved in the fibril core (Gremer et al. 2017). It has been 
suggested that these differences in atomic structure for Aβ40 and Aβ42 lead to a single Aβ 
species creating a homogeneous fibril composition (Xiao et al. 2015). Although some of 
these studies demonstrated that fibrils were cytotoxic in neuronal culture and contained 
structural features similar to in vivo pathology, they were generated with purely in vitro Aβ 
(Walti et al. 2016; Germer et al. 2017). The pathogenic potential of in vitro Aβ has been 
questioned in previous research studies using in vivo derived Aβ aggregates (Meyer-
Luehmann et al. 2006; Novotny et al. 2016). In an effort to resolve the structure of in vivo 
Aβ, fibrils grown from patient brain material have been analysed with ssNMR, avoiding the 
need for complex purification methods (Lu et al. 2013). This innovative method revealed that 
the structure of Aβ fibrils were different when derived from in vivo samples compared to 
traditional in vitro fibrils (Lu et al. 2013). One caveat to the in vitro propagation of in vivo 
Aβ is that it is unclear how representative these structures are within the brain and it is 
possible that a selection bias occurs. This is a well-described methodological issue for 
structural biology when using in vitro Aβ fibrils, where strict growth conditions must be used 
to produce a homogeneous fibril morphology that can then be resolved (Meier et al. 2017). 
Thus, growth conditions for fibrils can heavily influence the atomic structure and result in the 
selection of a single morphotype. The structural analysis of fibrils has provided atomic level 
detail but the pathological deposits of Aβ at the tissue level are also important to consider. 
 
Aβ pathologies 
In the progression of AD, it is well known that Aβ pathology can present in different forms. 
The earliest histological analysis of AD brain material described senile plaques, which were 
later identified as being made up of Aβ primarily (Alzheimer 1907; Divry et al. 1927; Wong 
	 20 
et al. 1985; Masters et al 1985). Additionally, Aβ can be deposited within the vasculature and 
is referred to as cerebral amyloid angiopathy or CAA, which can cause brain hemorrhaging 
(Glenner and Wong 1984). Distinguishing CAA from plaques is straightforward given their 
distinct locations, however neuropathologists have classified senile plaques into different 
categories using Aβ specific antibodies and amyloid dyes.  Plaques can generally be 
classified as either dense-cored or diffuse (Thal et al. 2006; Serrano-Pozo et al. 2011). As the 
name suggests, dense core plaques have a core which is positive for amyloid dyes like Congo 
Red or Thioflavin T, indicative of an ordered amyloid arrangement, while diffuse plaques 
lack this amyloid positive staining (Thal et al. 2006; Serrano-Pozo et al. 2011). Diffuse 
plaques are considered to be less important for AD progression and are more associated with 
a general aging phenotype (Thal et al. 2006; Serrano-Pozo et al. 2011). Conversely, dense-
cored plaques are considered to be specific for AD and are also the site of severe 
inflammation with activated microglia and reactive astrocytes (Serrano-Pozo et al. 2011; 
Heneka et al. 2015). Abnormal neuronal processes called dystrophic neurites, which are 
thought to be the main cytotoxic consequence of senile plaques, also surround these dense-
cored plaques (Thal et al. 2006; Serrano-Pozo et al. 2011). Dystrophic neurites can be 
identified by a number of different markers, one of which being hyperphosphorylated tau, the 
main component of NFTs (Serrano-Pozo et al. 2011). Aβ deposits have been further 
distinguished based on the location and the morphology of Aβ staining (Tagliavini et al. 
1988; Yamaguchi et al. 1988; Ikeda et al. 1989; Wisniewski et al. 1989; Dickson and Vickers 
2001; Maarouf et al. 2008). In addition to these extracellular pathologies of Aβ, it is also now 
clear that intracellular deposits can exist (LaFerla et al. 2007). However, the exact role of 
intracellular Aβ aggregates in disease is unclear, with some debate over whether this 
pathology occurs before or after extracellular deposits (LaFerla et al. 2007). The above 
classification of Aβ neuropathology has provided an overview of how pathology can appear 
in AD but bridging this information with detailed structural studies has been a challenge. 
 
Recently, classes of amyloid binding dyes called luminescent conjugated oligothiophenes 
(LCO) have provided an additional, unique tool for investigating aggregated protein deposits. 
These dyes contain multiple aromatic rings and bind to the repetitive β-sheet backbone in 
amyloids (Aslund et al. 2009). The specificity of this binding interaction can be further 
tailored by changing the number of rings in the LCO (Aslund et al. 2009; Herrmann et al. 
2015). This strong and specific binding is derived by the interaction between anionic side 
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groups of the LCO and the cationic amyloid residues, as the LCO lies parallel to the fibril 
axis (Herrmann et al. 2015; Schütz et al. 2017). Interestingly, the binding site of LCOs is 
distinct from the radiographic Aβ imaging compound Pittsburgh compound B (PiB) but is 
similar to X-34, an analogue of Congo Red (Bäck et al. 2016). The binding potential of LCOs 
has also been investigated from a therapeutic perspective for prion disease where LCOs were 
designed based on the structure of amyloid structures (Hermann et al. 2015). Perhaps one of 
the most powerful aspects of LCOs is that upon binding to the amyloid backbone there is a 
shift in the fluorescent emission spectra, which can distinguish between different amyloid 
deposits (Aslund et al. 2009). This additional information gained from histological staining 
has provided an opportunity to investigate the implication of pathology conformation on 
disease. 
 
2.2.2 Prion-like strains and clouds of conformation 	
In reference to: 
Rasmussen J*, Mahler J*, Beschorner N*, Kaeser SA, Häsler LM, Baumann F, Nyström S, 
Portelius E, Blennow K, Lashley T, Fox NC, Sepulveda-Falla D, Glatzel M, Oblak AL, 
Ghetti B, Nilsson KPR, Hammarström P, Staufenbiel M, Walker LC, Jucker M. Amyloid 
polymorphisms constitute distinct clouds of conformational variants in different etiological 
subtypes of Alzheimer's disease. Proc Natl Acad Sci U S A 2017b; 114: 13018-13023. 
(doi:10.1073/pnas.1713215114) 
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Although a number of different prion diseases have been identified in animals, not all PrPTSE 
sources are able to cause disease when introduced into a new species (Aguzzi et al. 2007; 
Collinge 2010). This species barrier effect as it has been defined, suggests there is an 
interaction between the PrPTSE agent and host PrPC where some level of compatibility is 
required to advance disease (Bruce et al. 1994; Aguzzi et al. 2007; Collinge 2010). It has 
been shown that the amino acid sequence of PrPC, and in particular polymorphisms at amino 
acid 129, can strongly influence the susceptibility of a host to prion disease (Palmer et al. 
1991; Collinge et al. 1996; Wadsworth et al. 2004; Collinge 2010). Astonishingly, with serial 
passaging of brain material into the same host species, the incubation period of prion disease 
can be drastically reduced as the species barrier is overcome (Aguzzi et al. 2007). This 
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phenomenon suggests some adaptation of PrPTSE structure occurs to enhance its infectious 
nature. This adaptation upon passaging has been hypothesized as occurring through two 
different mechanisms. The mutated selection scenario suggests that a new and mutated form 
of PrPTSE is formed during amplification that is more potent upon subsequent passage in a 
naïve host (Figure 3; Collinge 2010). More recently the idea of PrPTSE quasi-species was put 
forward that suggests multiple structures of PrPTSE exist in the brain, which are then selected 
for with passaging into a naïve host (Figure 3; Collinge 2010; Li et al. 2010). PrPTSE from 
different animals of the same species have also been demonstrated as having unique disease 
characteristics when inoculated into naïve hosts with PrPTSE (Pattison and Millson 1961; 
Fraser and Dickson 1973; Aguzzi et al. 2007). This is known as the strain concept, where 
different forms of PrPTSE exist while having an identical amino acid sequence, but distinct 
structural features that encode a biological activity (Collinge 2010). A number of different 
methods can be used to assess the strain properties of PrPTSE upon passage into a naïve host 
(Aguzzi et al. 2007). Most notably, strains can be distinguished by their pathobiology in a 
host (Aguzzi et al. 2007). A classic example is hamster-adapted transmissible mink 
encephalopathy (TME) where “hyper” and “drowsy” strains were described when hamsters 
were inoculated with TME PrPTSE (Bessen and Marsh 1992a; Bessen and Marsh 1992b; 
Bessen and Marsh 1994; Marsh and Bessen 1994). These two strains, as their name describes, 
led to opposite disease phenotypes with distinct deposition patterns and incubation times 
(Bessen and Marsh 1992b). Often the biochemical features can also differ between PrPTSE 
strains including post-translational glycosylation, resistance to proteolytic degradation or 
protein unfolding caused by detergents (Bessen and Marsh 1994; Collinge et al. 1996; Safar 
et al. 1998; Colby et al. 2009). An exemplary study identified eight different prion strains in 
hamsters based on their sensitivity to denaturing using a conformation-dependent 
immunoassay (Safar et al. 1998). These methods for identifying different strains of PrPTSE 
were also crucial in connecting the development of vCJD to the consumption of tainted beef 
and solidifying prion diseases as transmissible through environmental exposure (Collinge et 
al. 1996). The link between biochemical features of PrPTSE and their distinct properties in a 
new host is not only a fascinating biological phenomenon but also strong evidence for the 
protein-only hypothesis. 
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Figure 3. Two hypotheses for the evolving properties of prion agents upon experimental 
passage into a naïve host. In the “mutations” hypothesis, a new prion structure is formed in a 
new host, which is more pathogenic upon subsequent experimental passage and becomes the 
dominant amplified strain. Conversely, the “quasi-species” hypothesis suggests that multiple 
prion structures exist within a brain and that one structure is more pathogenic in a new host 
and becomes the dominant strain through amplification. 
 
Strain-like features of Aβ 
Similar to prion disease research, the investigation of strain-like properties of Aβ involves the 
inoculation of aggregates into transgenic mice to then investigate the features of induced 
pathology. This experimental paradigm is referred to as seeded nucleation, where structural 
features are amplified in a new host by templated misfolding (Jucker and Walker 2013; 
described in detail in 2.3.1). A seminal study utilized this model to investigate Aβ in the two 
transgenic mouse lines, APP23 and APPPS1, that have low and high ratios of brain Aβ42/40, 
respectively (Meyer-Luehmann et al. 2006). After intracerebral inoculation of brain extracts 
in young transgenic mice, different plaque morphologies developed (Meyer-Luehmann et al. 
2006). It was proposed that these strain-like morphotypes were encoded by the ratio of Aβ 
species produced in each mouse line (Meyer-Luehmann et al. 2006). Indeed, similar strain-
like features have been identified for in vitro seeded Aβ fibrils where distinct fibril structures 
could be propagated (Petkova et al. 2005). In a separate study, in vitro Aβ fibrils made using 
either Aβ40 or Aβ42 produced distinct pathologies in vivo (Stöhr et al. 2014). This distinct 
induced pathology was abolished when Aβ42 fibrils were grown in the presence of a 
denaturant to suggest the induced pathology was controlled by the structure of aggregates 
(Stöhr et al. 2014).  
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The previously described class of amyloid binding spectral dyes, known as LCOs, can also be 
used to identify structural differences between pathologies. Spectral discrimination of 
amyloid structure occurs through the twisting of the flexible LCO backbone upon binding to 
the β-sheet backbone resulting in a shifted emission spectrum (Nilsson et al. 2005). These 
distinct spectral properties were apparent when using an early version of LCOs to analyze 
different mouse-adapted prion strains (Magnusson et al. 2014). Similarly, the structure-
discriminating properties of LCOs also apply to the Aβ peptide. Using in vitro fibrillized 
Aβ40, the extent of fibril bundling as confirmed with atomic force microscopy was 
distinguished by the emission spectra of LCOs (Psonka-Antonczyk et al. 2016). As an 
extension of previous work investigating the strain-like features of in vivo Aβ pathology from 
APP23 and APPPS1 transgenic mice, LCOs were used to determine if the plaque core 
structure was also different in the induced pathology (Heilbronner et al. 2011). Distinct 
spectral emissions were identified in the induced pathology from the two mouse extracts, 
suggesting that these features are not only influencing the plaque morphology but also the 
amyloid core plaque structure (Heilbronner et al. 2011). 
 
Although the presence of strain-like Aβ aggregates is an interesting finding for in vitro or 
transgenic mouse material, it is important to determine whether such varied structures could 
exist in human AD. Distinct Aβ biochemical features have been identified in human AD 
patients with a unique disease progression characterized by rapid cognitive decline (Cohen et 
al. 2015). This rapid AD subtype is commonly referred to prion disease reference centers 
given the similar aggressive clinical phenotype but at autopsy standard AD pathology is 
observed (Schmidt et al. 2011). The conformation of Aβ42 in these rapid AD brains was 
quite heterogeneous and had abundant medium sized aggregates compared to sAD (Cohen et 
al. 2015). These biochemical distinctions were then speculated as being a potential reason for 
a different clinical presentation for disease (Cohen et al. 2015). However, it is important to 
note that these biochemical features were not propagated in an in vitro or transgenic mouse 
model, which is important for determining their strain-like properties (Aguzzi et al. 2007). A 
separate study satisfied this criteria by demonstrating that Aβ derived from patients harboring 
the Arctic mutation (E693G), which results in an amino acid change within the Aβ peptide 
sequence, displayed high susceptibility to denaturation and induced distinct, diffuse 
deposition in the vessels of transgenic mice compared to other AD extracts (Watts et al. 
2014). Additionally, the deposition of Aβ38 was prominent in mice inoculated with Arctic 
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Aβ (Watts et al. 2014). Two related studies also identified that distinct structures of Aβ could 
be propagated in vitro from different AD brain tissue samples (Lu et al. 2013; Qiang et al. 
2017). Similar to work by Cohen et al. (2015), rapid AD brain tissue contained different Aβ 
fibril structures than typical sAD and the posterior cortical atrophy variant of AD (PCA) 
(Qiang et al. 2017). Surprisingly, all samples showed fibril structure diversity when Aβ42 
was used as an in vitro substrate (Qiang et al. 2017). These studies provide evidence that 
atomic structural features propagated by brain derived Aβ can differ between subtypes of 
AD. However, as mentioned earlier, it is unclear how in vitro propagation may influence the 
selection and amplification of different Aβ structures, given that in vitro growth conditions 
can greatly influence the structure of Aβ and the heterogeneity of structures (Meier et al. 
2017). 
 
In order to further advance the knowledge surrounding Aβ structural variation in AD brain 
tissue, our recent study investigated a large cohort of patients with various etiologies using 
LCO spectral dyes (Rasmussen et al. 2017b). Specifically, both fAD (APP-V717I, PSEN1-
A431E, E280A, F105L) and sAD cases were investigated in addition to the PCA variant of 
AD. This diverse cohort of patient subtypes was also interrogated for regional brain 
differences, with temporal, occipital and frontal cortex samples being included. A previously 
established staining method for discerning Aβ pathology structure using the two LCOs, h-
FTAA and q-FTAA, was used to stain plaques in human tissue (Nyström et al. 2013). The 
collected fluorescent emission spectra indicated that certain fAD patients (APP-V717I and 
PSEN1-A431E) had obviously distinct plaques, both when considering the entire emission 
spectrum as well as using a ratio-metric analysis of fluorescent emission peaks for the two 
LCOs (502 nm/588 nm) (Rasmussen et al. 2017b). Subtle, but significant, differences were 
also seen between other groups of fAD and sAD patients, and notably between PCA and sAD 
patients (Rasmussen et al. 2017b). In agreement with other studies, there was no difference 
seen between brain regions for the spectral emission of amyloid plaque cores (Lu et al. 2013; 
Cohen et al. 2015; Qiang et al. 2017). Furthermore, while the mean plaque core structure was 
distinct between AD subtypes, it was observed that the spectral signature of single plaques 
did vary within a patient brain in a region-independent manner (Rasmussen et al. 2017b). 
This variation was referred to as clouds of amyloid core conformation and demonstrated that 
plaque structure has overlapping properties between AD etiologies and, notably, that there 
was substantial variation in the plaque conformation for sAD (Rasmussen et al. 2017b). This 
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observation drew parallels to prion studies where clouds of PrPTSE conformation were 
hypothesized as being responsible for strain adaptation with chemical treatment (Figure 3; Li 
et al. 2010; Collinge 2010). Spectral signatures for sAD and PCA cases were compared to 
clinical information (ApoE status, age and post-mortem interval) and Aβ biochemistry (Aβ 
amount, Aβ42/40 and protease resistance) but all of these factors were independent from the 
plaque spectral signature (Rasmussen et al. 2017b). Therefore, by inoculating the same 
amount of Aβ derived from APP-V717I, PSEN1-A431E and sAD brain extracts into 
transgenic APP23 mice, the ability of Aβ plaque structures to propagate was assessed similar 
to previous studies (Meyer-Luehmann et al 2006; Heilbronner et al. 2011; Watts et al. 2014; 
Rasmussen et al. 2017b). In addition, a unique human sAD case with low affinity PiB 
binding and divergent LCO spectral characteristics compared to typical AD was also injected 
into APP23 mice (Rosen et al. 2010). The amount and spectral signature of induced 
pathology differed between the injection groups to suggest different strain-like properties of 
AD derived Aβ (Rasmussen et al. 2017b). However, the induced amyloid core spectra did not 
perfectly mirror the difference seen in human tissue; a discrepancy that may be explained by 
the influence that host Aβ has on pathology (Meyer-Luehmann et al. 2006; Mahler et al. 
2015). 
 
This study was the first to investigate structural features of Aβ pathology in its native tissue 
environment and has provided insight into how subtypes of AD may be distinct at a 
molecular level. Astonishingly, these spectral differences were acquired from plaque cores 
that are indistinguishable using traditional staining methods (Rasmussen et al. 2017b). It is 
tempting to speculate that these differences in Aβ plaque structure could explain differences 
in clinical phenotype, especially for PCA and traditional sAD where distinct clinical 
phenotypes exist (Crutch et al. 2017). A more conservative interpretation of this data, which 
has direct implications to patients, is that this variation in plaque structure could decrease the 
efficacy of Aβ therapeutics (monoclonal antibodies) or diagnostic imaging, as indicated by 
the PiB negative sAD case (Condello and Stöhr 2018; Rasmussen et al. 2017b). The 
identification of conformational clouds is intriguing and is further supported by x-ray 
microdiffraction studies on human tissue samples, where plaque polymorphisms were 
identified within the same brain section (Liu et al. 2016). Another recent study identified Aβ 
structural variation within an AD brain using fluorescent dyes but even more variation 
between sAD patients, which aligns with our findings (Condello et al. 2018). However, it 
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will be important for future studies to isolate Aβ fibril structures from the brain that can then 
be used in structural studies as was recently reported for pathological tau in AD (Fitzpatrick 
et al. 2017). This would clarify if spectral properties correlate with atomic level structural 
variation in Aβ. 
 
The identification of Aβ plaque variation within AD that can be propagated is an intriguing 
finding whose relevance to the biology of disease still needs to be investigated. All samples 
used in the above study were collected from end-stage post-mortem AD patients where the 
disease is obviously at an advanced stage (McDade and Bateman 2017). As postulated by the 
amyloid cascade hypothesis, a perturbation in Aβ metabolism is the earliest event in disease 
(Selkoe and Hardy 2016). Some have even suggested that the involvement of Aβ in AD at 
later stages of disease is minor, as Aβ physiological changes reach a plateau late in disease 
(Holtzman et al. 2011; McDade and Bateman 2017). It follows that a perfect extension of 
these findings in end-stage human tissue would be to investigate the characteristics of Aβ 
over the course of maturing pathology. 
 
2.3 β-amyloid seeds 
2.3.1 The seeding paradigm 
 
As described earlier, multiple neurodegenerative diseases are characterized by the spreading 
of pathology throughout the brain (Jucker and Walker 2013; Brettschneider et al. 2015). An 
explanation for this spreading is a seeded nucleation model where pathologies spread along 
functionally connected networks of neurons through templated protein misfolding (Lee et al. 
2011; Jucker and Walker 2013). Characterizing the ability of misfolded forms of proteins to 
induce the conversion of naïve protein has strengthened the seeded nucleation model for 
prion-like proteins including Aβ and has led to a better understanding of the mechanism 
behind disease progression (Jarrett and Lansbury 1993; Jucker and Walker 2013; Walker and 
Jucker 2015).  
 
Numerous in vitro studies investigating Aβ fibrillization mirror the results found for PrPTSE. 
The ability of PrPTSE to seed aggregation of monomeric PrPC has been adapted into a number 
of in vitro methodologies. Specifically, these include protein misfolding cyclic amplification 
(PMCA), an amyloid seeding assay (ASA) and real-time quaking induced conversion (RT-
	 28 
QuIC) (Saborio et al. 2001; Colby et al. 2007; Atarashi et al. 2008). PMCA uses sonication 
to seed the aggregation of brain-derived PrPC with a test sample, and subsequent rounds are 
seeded with an aliquot of the previous cycle to amplify misfolded PrPTSE, which is detected 
by protease resistance (Saborio et al. 2001). Conversely, the principles of RT-QuIC and ASA 
utilize recombinant forms of PrPC (Colby et al. 2007; Atarashi et al. 2008). In these methods, 
the fluorescence of thioflavin T (ThT) is used to monitor protein aggregation while a sample 
is intermittently agitated (Colby et al. 2007; Atarashi et al. 2008). A number of ThT assays 
have been developed to investigate the aggregation of Aβ (Cohen et al. 2012; Morgado et al. 
2012; Nagarathinam et al. 2013). In general, these assays have clearly defined Aβ 
aggregation proceeding in a sigmoidal fashion with a slow nucleating or lag phase, followed 
by rapid fibril growth and finally, a plateau phase when the system is saturated (Figure 4; 
Knowles et al. 2014; Meisl et al. 2014). These assays have been particularly valuable in 
defining the kinetics of aggregation and determining different mechanisms by which seeded 
nucleation can occur (Figure 4; Knowles et al. 2014; Meisl et al. 2014). The two main 
mechanisms defined by these assays are primary and secondary nucleation, which are 
distinguished by the aggregation curve rate constant (Knowles et al. 2014; Meisl et al. 2014). 
From an atomic scale, primary nucleation occurs when a seed forms and a fibril grows from 
this seed, while secondary nucleation occurs when a new seed is formed at the surface of an 
already existing fibril which leads to a second, separate extending fibril (Knowles et al. 2014; 
Meisl et al. 2014). Additionally, ThT assays identified that fragmentation of fibrils produces 
more surfaces for extension of amyloid growth and, consequently, a distinct aggregation 
curve (Knowles et al. 2014). ThT assays have also been used to investigate the ability of 
different Aβ samples to induce aggregation of recombinant Aβ by analyzing the duration of 
the lag phase. The lipid membrane has been demonstrated as a site of potent Aβ seed 
generation capable of rapidly causing fibril extension in samples from a novel transgenic 
mouse model with membrane anchored Aβ species (Nagarthinam et al. 2013). A subsequent 
study used the same methodology to further elucidate that mitochondrial membrane 
associated Aβ is an efficient seed of aggregation (Marzesco et al. 2016). The controlled 
environment of in vitro ThT assays has added invaluable mechanistic insights into the 
seeding ability of Aβ but further in vivo evidence has solidified the relevance of this 
paradigm to disease. 
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Figure 4. Amyloid aggregation proceeds in three phases. During the lag phase, monomeric 
peptide is in solution and there is little to no aggregation. Upon formation of a nucleus or 
seed, aggregation of monomeric protein occurs in ordered β-sheet rich fibrils, which elongate 
in the extension phase. The extension phase is quite dynamic with monomers being added to 
fibrils but also fragmentation of the fibril and the release of monomeric peptide. The final 
plateau phase is characteristic of a saturated system where many aggregates are present. 
 
In vivo seeding 
Using transgenic models of cerebral β-amyloidosis, the concept of seeded aggregation has 
been elegantly demonstrated as a robust mechanism for amyloid pathology onset. As 
mentioned earlier, the APP23 and APPPS1 models have been used to demonstrate that Aβ 
laden brain extracts can induce pathology within the hippocampus of APP transgenic mice 
while control WT extracts do not induce deposition (Meyer-Luehmann et al. 2006). Similar 
findings of seeded induction of Aβ pathology were also reported using a novel transgenic 
mouse with a bioluminescence reporter for astrocytic gliosis (Watts et al. 2011; Stöhr et al. 
2012). In these mice, an increased bioluminescent signal represents Aβ pathology induced 
gliosis, and with this tool the injection of Aβ-laden brain extracts was confirmed to spur Aβ 
deposition (Watts et al. 2011; Stöhr et al. 2012). The earlier onset of Aβ deposition caused by 
misfolded Aβ strongly supports the seeded nucleation of pathology, but subsequent studies 
added to this by using transgenic models where endogenous pathology does not occur in the 
transgenic hosts (Morales et al. 2012; Rosen et al. 2002). This de novo induction of Aβ 
pathology through injection of AD brain extracts in transgenic rodents was crucial to showing 
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that aggregated Aβ can seed the deposition of endogenous Aβ (Morales et al. 2012; Rosen et 
al. 2002). Further, seeded deposition of Aβ was demonstrated in a hippocampal slice culture 
model, where pathology could be induced with the application of an aged transgenic brain 
extract (Novotny et al. 2016). Although the seeded deposition of Aβ in vivo is a robust 
phenomenon, it is unclear which mechanism identified in vitro, namely primary nucleation or 
secondary nucleation, is dominant in a tissue environment (Knowles et al. 2014). These 
mechanisms likely occur simultaneously for endogenous pathology in transgenic models of 
cerebral β-amyloidosis, perhaps with primary nucleation being dominant early in pathology, 
but secondary nucleation being more prevalent later. It is also interesting to speculate that, in 
a seeding paradigm where a brain extract containing aggregated Aβ is focally injected, 
secondary nucleation may preferentially occur at the surface of these injected aggregates. A 
number of other factors not accounted for in in vitro experiments like inflammation, Aβ 
production and the tissue environment itself, would likely heavily influence Aβ aggregation 
kinetics. 
 
The above in vitro and in vivo models have supported the seeding abilities of Aβ but whether 
this is a relevant mechanism within AD remains unclear (Selkoe and Hardy 2016; Rasmussen 
et al. 2017a). Recent evidence from human post-mortem brain tissue has provided some of 
the most convincing data thus far for Aβ pathology being transmissible in humans in a seeded 
nucleation model (Jaunmuktane et al. 2015; Frontzek et al. 2016; Hamaguchi et al. 2016; 
Kovacs et al. 2016; Ritchie et al. 2017; Cali et al. 2018). A seminal study found that human 
cases of CJD caused by the injection of growth hormone prepared from PrPTSE-contaminated 
pituitary extracts had substantial Aβ pathology (Jaunmuktane et al. 2015). The amount of Aβ 
could not be explained by other factors, such as age or genetic status and thus, it was 
proposed that the pituitary extracts containing PrPTSE also harbored Aβ aggregates that 
induced pathology (Jaunmuktane et al. 2015). A series of later studies identified that CJD 
caused by dura mater grafts contaminated with PrPTSE also resulted in some cases displaying 
Aβ pathology above the expected level (Frontzek et al. 2016; Hamaguchi et al. 2016; Kovacs 
et al. 2016; Cali et al. 2018). This ruled out that Aβ pathology was spurred by injection of 
growth hormone and corroborated the interpretation that Aβ pathology may indeed be 
transmitted. Finally, similar unexpectedly high levels of Aβ pathology were found in patients 
that received growth hormone treatment but did not have CJD, removing any confounding 
possibility of PrPTSE causing Aβ pathology (Ritchie et al. 2017). This series of studies on 
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human post-mortem tissue has provided credible evidence for the prion-like features of Aβ in 
humans and its central role in causing pathology. It is important to note that robust tau 
pathology was not seen in these cases, meaning that these patients did not reach the 
pathological or cognitive criteria required for the AD classification. However, it is possible 
that the incubation period was not long enough for tau pathology to develop, which normally 
follows Aβ deposition in AD. It will be crucial for future work to determine whether Aβ 
alone can induce full-blown AD with tau pathology in either an appropriate model system or 
in humans where environmental exposure to Aβ occurred very early in life. 
 
The seeding paradigm has provided a valuable construct for understanding Aβ pathology and 
the likely mechanism behind its appearance in disease. Relying on the above paradigm and 
methods, recent work has aimed to better understand the abilities of different Aβ sources to 
seed deposition in a naïve host. 
 
2.3.2 The age-dependency of β-amyloid seeding potency 	
In reference to: 
Ye L*, Rasmussen J*, Kaeser SA, Marzesco A, Obermueller U, Mahler J, Schelle J, 
Odenthal J, Krueger C, Fritschi SK, Walker LC, Staufenbiel M, Baumann F, Jucker M. Aβ 
seeding potency peaks in the early stages of cerebral β-amyloidosis. EMBO Rep 2017; 18: 
1536-1544. 
(doi:10.15252/embr.201744067) 
*equal contribution 
	
 
Indeed, not all aggregated Aβ samples harbor the same ability to seed aggregation of 
monomeric Aβ. In the first investigations of Aβ seeding properties in vivo it was found that 
while brain derived Aβ seeds were very efficient at inducing deposition, in vitro Aβ fibrils 
were poor seeds (Meyer-Luehmann et al. 2006). This was some of the first evidence that 
aggregated Aβ can have varying seeding properties. Astonishingly, the ability of in vitro Aβ 
to seed deposition in vivo was greatly enhanced using a slice culture assay to amplify amyloid 
prior to injection (Novotny et al. 2016). This suggests that a tissue environment can play a 
central role in forming potent seeds. It has since been demonstrated that in vitro Aβ 
aggregates can seed deposition in vivo if large amounts are injected and the aggregation 
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conditions are altered (Stöhr et al. 2014). The seeding potency of in vivo derived Aβ was 
further investigated using ultracentrifugation to separate soluble and insoluble fractions 
(Langer et al. 2011). While the soluble Aβ fraction contained substantially less Aβ than the 
insoluble fraction (>1000-fold), both extracts induced a comparable amount of Aβ pathology 
in APP23 mice (Langer et al. 2011). Additionally, the soluble Aβ seeds were sensitive to 
digestion by a protease but the same digestion protocol did not completely remove the 
seeding ability of the total extract (Langer et al. 2011). Similarly, potent soluble Aβ seeds 
were identified in the human AD brain, where extremely low levels of Aβ (<10-18 moles) 
seeded Aβ deposition in APP23 mice (Fritschi et al. 2014a). Conversely, Aβ aggregates 
obtained from the cerebrospinal fluid of AD patients did not seed Aβ deposition in vivo 
(Fritschi et al. 2014a). This difference in seeding ability was attributed to the smaller size of 
aggregates in CSF compared to the soluble AD brain fraction (Fritschi et al. 2014a). As 
mentioned earlier, Aβ formed in different lipid environments can also greatly increase the 
potency of seeding both using ThT aggregation assays and in vivo inoculations (Marzesco et 
al. 2016). 
 
The infectious titer of a disease agent is a crucial characteristic for assessing its risk for a 
population. This has been achieved for decades using in vivo bioassays where the titration of 
a sample determines its potency (Reed and Munch 1938). Typically, the inoculation of naïve 
hosts with a dilution series of the infectious agent allows for the determination of the dilution 
at which 50% of inoculated animals die, also known as the lethal dose 50 or LD50 (Reed and 
Munch 1938). In this way, different isolates can be compared for their pathogenicity. 
Bioassays are also used extensively in prion diseases to determine how infectious certain 
PrPTSE isolates are (Prusiner et al. 1982). When considering models of Aβ seeded deposition, 
an obvious hurdle for determining potency of a sample is that the transgenic animals used in 
a seeding paradigm do not have robust symptoms associated with pathology (Meyer-
Luehmann et al. 2006). Indeed in vivo Aβ can be extensively diluted while still producing 
seeded deposition of Aβ in transgenic mice but the potency of Aβ extracts has not been 
addressed (Fristchi et al. 2015; Morales et al. 2015). 
 
In an effort to simultaneously design a precise Aβ seeding bioassay and also determine how 
Aβ seeding properties evolve over the course of cerebral amyloidosis, our recent study used 
two models of Aβ deposition, namely, APP23 and APPPS1 (Ye et al. 2017). The maximum 
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life span was assessed for each mouse line and age groups were defined in order to have six 
time points for each transgenic model (Ye et al. 2017). Histological and ELISA 
measurements of Aβ40 and Aβ42 determined that pathology and protein levels increase 
during aging for both lines as expected (Ye et al. 2017). Intriguingly, the ratio of Aβ42/40 
was not constant over the course of aging and peaked in both lines at the earliest time point 
where pathology was detected with histology (Ye et al. 2017). Pooled brain extracts from the 
different age groups of mice were then serially diluted and injected into young transgenic 
APP23 mice. In this standard seeding paradigm, mice were aged for a fixed six-month period 
and subsequently sacrificed to assess Aβ pathology in the hippocampus. The numbers of 
mice with induced pathology were recorded for each extract age and dilution, similar to the 
number of dead mice in a bioassay for a lethal agent, and the seeding dose 50 (SD50) was 
calculated in order to assess the seeding activity (Ye et al. 2017). While the seeding activity 
plateaued for both mouse lines at later time points, the specific seeding activity (calculated by 
taking into account the amount of Aβ present within the extract) displayed a peak in both 
lines (Ye et al. 2017). Astonishingly, this peak coincided with the age where Aβ42/40 was 
highest (Ye et al. 2017). This simultaneous change in Aβ biochemistry and specific seeding 
activity near the onset of pathology provides an interesting perspective about Aβ deposition 
and perhaps even AD onset. 
 
The robust nature of this finding in two models both with early and late onsets suggests that 
targeting these unique Aβ species at the earliest stages is likely crucial for successful disease 
mitigation (McDade and Bateman 2017). Designing a therapeutic treatment directed against 
Aβ at the earliest stages of AD will require exquisite biomarkers to identify when Aβ 
pathology first develops. Likely these biomarkers could then be assessed in at risk 
populations of people based on thorough genetic testing, allowing for accurate prediction of 
disease onset and thus, appropriate therapeutic intervention (McDade and Bateman 2017). 
The targeting of Aβ seeds is an enticing strategy but further analysis of the exact nature of 
these Aβ aggregates will be crucial for designing potent therapeutics. 
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2.4 Isolating bioactive in vivo Aβ seeds 
2.4.1 The varied forms of aggregated β-amyloid 
 
While larger amyloid structures have been discussed thus far, a number of different Aβ 
multimers with various properties have also been identified. Following the cleavage of APP 
in the amyloidogenic pathway, monomeric Aβ is then free to aggregate into higher order 
structures. As outlined in the amyloid cascade hypothesis, this misfolding of Aβ is believed 
to be responsible for subsequent alterations in brain physiology and finally neurodegeneration 
(Selkoe and Hardy 2016). 
 
The monomeric form of Aβ has not been clearly identified as having a biological effect in the 
brain but even at the level of dimer formation this changes. Early reports found that stable 
small oligomers such as dimers and trimers are produced by living cells (Podlisny et al. 1995; 
Walsh et al. 2000; Walsh et al. 2002). When isolated from cells, cerebrospinal fluid and even 
the brain, Aβ dimers were capable of inhibiting long-term potentiation (Walsh et al. 2002; 
Klyubin et al. 2008; Shankar et al. 2008). These and similar reports were key in producing 
interest in soluble oligomers of Aβ to complement the body of research on the pathological 
hallmark of senile plaques (Haass and Selkoe 2007). A soluble dodecamer of Aβ, termed 
Aβ*56, identified in transgenic mice has also been associated with memory impairment in a 
number of studies (Lesne et al. 2006; Lesne et al. 2008; Lesne et al. 2013; Liu et al. 2015; 
Amar et al. 2017). Structurally, Aβ*56 is assembled from Aβ trimers while existing in 
membrane-associated fractions (Lesne et al. 2006). In human subjects, Aβ dimers, trimers 
and Aβ*56 all increase with age and in disease, but Aβ*56 correlated best with synaptic 
deficits and pathological tau (Lesne et al. 2013). This distinct Aβ*56 assembly has been 
hypothesized as an off-pathway aggregate, separate from Aβ fibrillar structures, based on its 
unique structural properties, temporal occurrence early in disease and location within in the 
brain (Lesne et al. 2013; Liu et al. 2015). A recent study has implicated Aβ*56 as eliciting its 
neuron altering effects by interacting with N-methyl-D-aspartate receptors, increasing 
intracellular calcium concentration and finally inducing tau phosphorylation and missorting 
within neurons (Amar et al. 2017). 
 
In addition to the in vivo-derived oligomers mentioned above, Aβ-derived diffusible ligands 
(ADDL) are an oligomeric preparation from in vitro studies that also have suggested 
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neurotoxic effects (Lambert et al. 1998; Wang et al. 2002; Gong et al. 2003). ADDLs are 
composed of Aβ42 and have since been identified as a subpopulation of multiple Aβ 
assemblies, as opposed to a single multimeric aggregate (Hepler et al. 2006). In a separate 
study, a slightly different Aβ oligomer preparation showed similar neurotoxicity in cell 
culture but an antibody specific for medium sized oligomers abolished this toxicity, 
suggesting that moderately sized oligomers are the toxic entity (Kayed et al. 2003). A slightly 
larger version of ADDLs have also been identified in vitro with a similar “doughnut” 
appearance under an electron microscope that are referred to as annular assemblies (Lashuel 
et al. 2002; Bitan et al. 2003;). These annular species have an intermediate size when 
compared to larger fibrils and lack a fibrillar ultrastructure (Haass and Selkoe 2007). Small 
but fibrillar Aβ assemblies, known as protofibrils, are also described as stable Aβ assemblies 
(Hartley et al. 1999; Walsh et al. 1999). These protofibril structures have a more ordered β-
sheet structure and have the ability to continue fibrillization and become mature amyloid 
fibrils (Harper et al. 1999; Walsh et al. 1999). There has been conflicting information about 
whether protofibrils are toxic and impair neuron function or are rather benign structures 
(Hartley et al. 1999; Walsh et al. 1999; Liu et al. 2015). The role of these different Aβ 
populations and the end-stage Aβ fibrils/deposits has been a central debate in AD research, 
with some arguing oligomers should be a focus of research since senile plaques do not 
correlate with neurodegeneration (Giannakopoulos et al. 2003; Haass and Selkoe 2007). 
However, it is worth mentioning that the extensive inflammatory reaction and neuritic injury 
surrounding dense-cored plaques is damaging to the tissue environment and thus senile 
plaques are also detrimental, at least indirectly, as opposed to only oligomeric Aβ (Serrano-
Pozo et al. 2011; Heneka et al. 2015). While the physiological effect of Aβ on neurons is 
important to consider when describing Aβ subpopulations, the ability of different structures 
to induce fibrillization should be investigated, given that this is the first event of AD (Selkoe 
and Hardy 2016). As mentioned previously, brain extracts containing extensive aggregated 
Aβ are capable of inducing deposition in vivo (Rasmussen et al. 2017b; Ye et al. 2017). 
Interestingly, soluble fractions of these brain extracts are extremely potent inducers of Aβ 
deposition (Langer et al. 2011; Fritschi et al. 2014a). This could suggest that certain 
oligomeric species of Aβ outlined above may play a particularly important role in inducing 
Aβ pathology. 
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The presence of aggregated Aβ is indeed a central characteristic of AD and is thus a potential 
target of disease modifying therapy. Given the various Aβ species outlined above, it is 
important to identify how different therapies can target specific Aβ assemblies in vivo and 
whether such subpopulations are more efficacious at slowing disease. 
 
2.4.2 Finding a suitable target for Alzheimer’s disease therapies 	
In reference to: 
Rasmussen J, Bühler A, Baumann F, Jucker M. An agarose gel fractionation method for 
enriching brain derived proteopathic seeds. in preparation 
	
 
The successful treatment of AD progression has been elusive to researchers and clinicians 
thus far (Karran and Hardy 2014). Early treatments were based on observations that there 
were low levels of the choline acetyltransferase enzyme, a crucial enzyme in the production 
of the neurotransmitter acetylcholine, in AD patients with associated cholinergic neuron 
death (Bowen et al. 1976; Perry et al. 1977; Francis et al. 1999). Unfortunately, these 
treatments have not slowed the progression of disease but rather treated symptoms in AD 
patients.  
 
Based on the amyloid cascade hypothesis, a number of strategies for modulating Aβ 
production/clearance have been developed to target the earliest trigger of disease (Karran and 
DeStrooper 2016). When targeting the production of Aβ, inhibitors of secretases have been 
used in order to alter APP processing (Voytyuk et al. 2017). Early identification of small 
molecules that reduced Aβ release in cell culture were found to act on the γ-secretase 
complex (Karran and De Strooper 2016). However, off-target effects of these γ-secretase 
inhibitors were identified during in vivo testing due to the many substrates that the γ-
secretase acts on (Doody et al. 2013; Voytyuk et al. 2017). Recent work has even suggested, 
that a now defunct γ-secretase inhibitor, semagacestat, which failed in Phase 3 testing, may 
not completely inhibit APP cleavage, but rather alter Aβ subcellular localization (Doody et 
al. 2013; Tagami et al. 2017). There are now suggestions for targeting γ-secretase at the level 
of modifying cleavage of APP to reduce Aβ42 production rather than completely inhibiting 
enzyme activity, which produces undesirable side effects (Voytyuk et al. 2017). There is 
evidence that instability of the γ-secretase complex may be at the root of changes in APP 
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cleavage and, as such, a treatment that stabilizes this complex may be a suitable disease 
modifying strategy (Szaruga et al. 2017). Similar targeting of the β-secretase, BACE1, with 
small molecules has produced promising results (Vassar et al. 2014). Complete inhibition of 
this enzyme complex has produced less severe side effects and has subsequently been 
vigorously pursued as an AD treatment (Vassar et al. 2014; Shimshek et al. 2016). In animal 
models, BACE1 inhibitors have demonstrated a potent reduction in Aβ (Vassar et al. 2014; 
Kennedy et al. 2016; Schelle et al 2016; Villarreal et al. 2017). However, recent failure of a 
BACE1 inhibitor, verubecestat in Phase 2/3 human trials was again a troubling set back for 
AD therapeutics (Hawkes 2017). Additionally, a recent study highlighted that inhibition of 
BACE1 can shift APP processing towards η-cleavage and produce neurotoxic peptides 
(Willem et al. 2015). Although targeting secretases for modification holds some promise for 
reducing Aβ and treating AD, a critique of this strategy is that already formed Aβ aggregates 
and pathology are not targeted. 
 
Another main focus of AD therapeutics is improving the clearance of Aβ (Karran and De 
Strooper 2016). Indeed, after Aβ is produced, it can leave the brain through bulk flow in the 
interstitial fluid where it is later degraded in the periphery, but this is a challenging target for 
therapies (Wang et al. 2017). Early work spurred interest in specifically targeting the Aβ 
peptide by showing that vaccination with Aβ (active immunization) reduced Aβ levels in 
APP transgenic mice (Schenk et al. 1999; Morgan et al. 2000). Another seminal study was 
instrumental in showing that Aβ can be cleared through phagocytosis by microglia after 
passive immunization with an Aβ-specific antibody (Bard et al. 2000). These results in 
transgenic mouse models were also confirmed in human studies where Aβ immunotherapy 
was shown to reduce Aβ pathology (Rinne et al. 2010; Ostrowitzki et al. 2012; Sevigny et al. 
2016). A number of different immunotherapies are in various phases of clinical trials, each 
with slightly different binding properties to the different forms of Aβ mentioned above 
(Ostrowitzki et al. 2012; Doody et al. 2014; Sevigny et al. 2016). Solanezumab is an 
antibody developed by Eli Lilly & Co. with affinities toward monomeric Aβ and small 
soluble oligomers that was first produced in mice by immunizing with an N-terminal Aβ 
epitope (Doody et al. 2014). In Phase 3 trials, slowed cognitive decline was suggested with 
solanezumab infusion but only in subjects with mild symptoms (Doody et al. 2014). This 
significant effect was then lost in patients with more advanced stages of disease (Doody et al. 
2014). Another Aβ form has been targeted in AD trials with both aducanumab and 
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gantenerumab (Biogen and Roche, respectively), which are selective for Aβ aggregates 
(Ostrowitzki et al. 2012; Sevigny et al. 2016). Interestingly, aducanumab was identified by 
screening B-cell clones isolated from cognitively normal aged humans while gantenerumab 
was developed more traditionally through screening a humanized phage library for binding to 
aggregated Aβ (Ostrowitzki et al. 2012; Sevigny et al. 2016). A study in human subjects has 
demonstrated that gantenerumab can reduce Aβ load within the brain; however, effects on 
cognition have not been clear (Ostrowitzki et al. 2012). Excitingly, results from both 
transgenic mouse models and human clinical trials have suggested that aducanumab reduces 
Aβ levels in the brain and moderately slows cognitive decline (Sevigny et al. 2016). This 
immunotherapy research has demonstrated that even aggregated Aβ can be targeted for 
removal, suggesting that AD progression could be stopped and perhaps even slight 
improvements made. There are two current ideas about how to improve the efficacy of Aβ 
immunotherapies even further, one is to intervene as early as possible in AD to stop the 
cascade of neurodegeneration, and the other is to ensure that therapies are targeting the most 
bioactive populations of Aβ (Haass and Selkoe 2007; McDade and Bateman 2017; Ye et al. 
2017). Thus, it is important to develop therapeutics that target Aβ species that have a well 
defined biological role in disease. 
 
We recently developed a new methodology that shows promise for isolating subpopulations 
of Aβ from in vivo sources using gel fractionation, which in turn can be used in downstream 
applications (Rasmussen et al., in preparation). This agarose gel electrophoresis method for 
resolving larger aggregates of amyloid proteins was adapted for a finer analysis of aggregates 
within the gel matrix by isolating different agarose fractions (Bagriantsev et al. 2006). 
Different in vitro preparations of Aβ, namely monomers, ADDLs and fibrils, migrated in an 
expected manner, with progressively higher molecular weight migration patterns, 
respectively (Rasmussen et al. in preparation). For in vivo-derived brain extracts rich in 
aggregated Aβ, it was determined that Aβ migrated differently from in vitro samples with the 
majority of Aβ being found in the highest and lowest molecular weight fractions across many 
age groups (Rasmussen et al. in preparation). Such discrepancies between in vitro and in 
vivo Aβ could represent the reason that these two forms have substantially different in vivo 
seeding activities (Meyer-Luehmann et al. 2006; Novotny et al. 2016). A crucial advance of 
this new methodology was the liberation of Aβ from the solid agar fractions through 
enzymatic digestion (Rasmussen et al. in preparation). Aβ migrating at a high molecular 
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weight from an aged APP23 brain extract even retained quaternary structure, as shown by 
binding to a conformational amyloid-specific antibody and inducing seeded deposition in 
APP23 mice after intracerebral inoculation (Rasmussen et al. in preparation). 
 
Considering the above studies on immunotherapy in AD, the agarose fractionation 
methodology can have a number of applications. Perhaps most exciting would be the 
comparison of candidate antibodies in their binding profile to native in vivo Aβ samples as 
performed by immunoprecipitation on different fractions (Rasmussen et al., in preparation). 
This would greatly enhance our understanding of how exactly therapeutic antibody 
candidates differentially recognize the various subpopulations of Aβ outlined above (Haass 
and Selkoe 2007). Additionally, this novel methodology can be used to generate immunogens 
composed of distinct Aβ aggregate sizes, which can then be used for the generation of novel 
therapeutics. These distinct fractions of Aβ can also be analyzed for seeding potency to 
determine the size fraction where the most potent seeds are present (Ye et al. 2017). The use 
of agarose fractionation could immediately advance our understanding of Aβ seeding and 
help to target the most bioactive species and subsequently neutralize this initial trigger of AD. 
Such rational and targeted disease intervention may provide the strategy necessary for 
slowing the cognitive decline that plagues AD patients. 
 
2.5 Conclusions and outlook 
 
The amyloid cascade hypothesis has had a dominant influence on the research strategies 
surrounding AD in recent decades (Karran and De Strooper 2016; Selkoe and Hardy 2016). 
This focus on Aβ misfolding and seeded nucleation as the seminal event responsible for 
setting off a cascade culminating with neurodegeneration has led to an enhanced 
understanding of Aβ production, clearance and physiological effects. Within this dissertation, 
it has been demonstrated that Aβ plaque core morphology is distinct between AD subtypes 
and can be propagated, but also that plaque core conformation varies within a single AD 
brain (Rasmussen et al. 2017b). Working on this conclusion of Aβ-related differences late in 
disease, a subsequent investigation used APP transgenic mice to focus on pathology onset, 
which has been implicated as a crucial point in AD (McDade and Bateman 2017; Ye et al. 
2017). It was conclusively shown that Aβ at the earliest stages of pathology possesses a 
different specific seeding activity and distinct biochemical features, compared to advanced 
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disease (Ye et al. 2017). These two studies outlined that Aβ structures can vary within AD 
and likely over the course of disease as well, emphasizing that a method is needed to further 
analyze these aggregates from in vivo sources. Finally, the use of agarose fractionation was 
shown to adequately separate Aβ by size while retaining structural and biological features to 
facilitate downstream application for sample analysis and therapeutic development 
(Rasmussen et al, in preparation). 
 
When considering this body of work as a whole, it is clear that future research will need to 
determine how these principles overlap on multiple levels. A central question out of the first 
study is whether Aβ plaque core structural variation meaningfully alters the course of AD. 
Particularly, the substantial variation in plaque conformation for sAD patients begs the 
question whether the diverse symptomology in AD may be encoded in Aβ structure. In line 
with this, it would be interesting to investigate Aβ pathology with LCOs in brains from rapid 
AD and individuals with high Aβ burden but normal cognition as two ends of the spectrum 
for cognitive function (Schmidt et al. 2011). If there was a distinction between these extreme 
groups of neurodegeneration with Aβ pathology it would further suggest that conformational 
variation influences disease. It is also important to determine whether structural variation in 
oligomeric Aβ can distinguish patient groups given its hypothesized active role in AD (Haass 
and Selkoe 2007). This question could be answered by using agarose fractionation to isolate 
oligomeric fractions for structural analysis (Rasmussen et al. in preparation). If multiple 
forms of aggregated Aβ were distinct at a structural level in different AD etiologies at the 
end-stage of disease it could suggest that this structural variation has a role in determining 
AD progression and symptoms. 
 
The variation in Aβ pathology conformation at the end-stage of disease was striking, but 
whether this is also found at early stages of disease remains unknown (Rasmussen et al. 
2017b). If Aβ aggregates were distinct between AD patients with different clinical 
presentations early in disease, it could suggest that this conformational variation influences 
disease progression as opposed to being an artifact produced late in disease. The findings in 
transgenic models of cerebral β-amyloidosis have demonstrated that Aβ aggregates do 
change with aging but the strain-like morphotypes produced after seeding from different 
models are preserved throughout aging (Ye et al. 2017). Thus, it could be that early versions 
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of pathogenic Aβ would also be distinct between certain patients with disparate end-stage 
pathology. 
 
Given that most interventions targeting Aβ are moving to primary prevention, emphasis 
should be placed on Aβ features during this early stage of pathophysiology (McDade and 
Bateman 2017). Although investigating early populations of Aβ has been possible with 
transgenic mice (Ye et al. 2017), this is obviously a difficult human sample to obtain. More 
explicitly: Which young individuals without cognitive symptoms have pathogenic Aβ that 
would set off a cascade leading to AD decades later? It would be of interest to investigate Aβ 
in biological fluids by different conformational means to determine whether distinctions can 
still be made for patients, both with advanced AD and earlier stages of mild-cognitive 
impairment. Although still a challenge, the collection of CSF from people at risk of 
developing AD is possible, for example with ApoE4 carriers or fAD mutation carriers like 
those enrolled in the Dominantly Inherited Alzheimer’s Network (DIAN) (Bateman et al. 
2012; Karch and Goate 2015). Although, CSF and brain derived Aβ have different seeding 
capabilities and aggregate sizes, it could be that Aβ in the CSF retains some structural 
elements to distinguish patients (Fritschi et al. 2014a). The application of LCOs or other 
conformation sensitive methods to such biological fluids could prove invaluable for this 
strategy and is an obvious avenue for continued research. 
 
From a translational perspective, the Aβ structural variations described in human brain tissue 
with LCO dyes have immediate implications for the treatment of AD (Rasmussen et al. 
2017b; Condello and Stöhr 2018). One method for assessing the disease status of suspected 
AD patients is the retention of the PiB compound or similar radioligands within the brain, 
which identify Aβ based on amyloid conformation (Klunk et al. 2004; Clark et al. 2012; 
Wolk et al. 2012). It has already been demonstrated that a unique case with sAD had a 
reduced retention of PiB, despite the brain being populated with plaques (Rosen et al. 2010). 
Although PiB and other PET ligands have proven an accurate indication of Aβ burden within 
the brain across the human population, it is important to note that structural variation of Aβ 
plaques identified here could complicate these findings (Klunk et al. 2004; Wolk et al. 2012; 
Clark et al. 2012; Rasmussen et al. 2017b). 
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Perhaps one of the more striking speculations based on the above results is that variation in 
Aβ plaque conformation could impact the efficacy of an anti-Aβ immunotherapy (Rasmussen 
et al. 2017b). The somewhat underwhelming results of immunotherapy in AD could be 
partially explained by this variation (Condello and Strohr 2018). In order to answer this 
question and determine whether antibodies against Aβ vary in their binding to individual 
patients, agarose fractionation could be applied (Rasmussen et al. in preparation). As 
demonstrated for commercial antibodies, immunoprecipitation from different size fractions 
could be used to assess a variety of patient samples with current Aβ immunotherapy 
candidates using in vivo material under physiological conditions (Rasmussen et al. in 
preparation). This could be used to confirm the efficacy of antibody-binding to amyloid 
aggregates present in a broad range of patients before initiating immunotherapy trials. 
 
Another extension of the agarose fractionation methodology is that after enriching a potent 
Aβ seed fraction, perhaps generated with early-stage Aβ aggregates (Ye et al. 2017), 
structural analysis with methods like cryo-electron microscopy could be pursued. Combining 
structural analysis with drug design could yield a potent treatment as was recently shown for 
PrPTSE and LCOs (Herrmann et al. 2015). More traditional methods like active immunization 
in a naïve animal could also be pursued to generate novel immunotherapies. Alternatively, 
the more recent use of humanized phage libraries has allowed for high-throughput, in vitro 
screening of samples to identify binding partners of Aβ (Droste et al. 2015; Munke et al. 
2017). Such a strategy using either a naïve library or an Aβ-primed library paired with 
screening specific size fractions of potent in vivo Aβ seeds would likely identify a novel 
immunotherapy. The advantage of utilizing agarose fractionation is that a disease-relevant 
immunogen could be isolated from a desired biological sample that can be thoroughly 
characterized with other biochemical and biological methods in parallel with the development 
of a therapy. 
 
In conclusion, Aβ has long been identified as a central player in AD pathology, but more 
recently as a hypothesized trigger of disease itself (Selkoe and Hardy 2016). The prion-like 
properties of Aβ have further intensified focus on the mechanism by which amyloidogenic 
misfolding occurs and elicits neurodegeneration (Jucker and Walker 2013). The diverse 
methods and models used in this dissertation have provided evidence for Aβ conformational 
and biological characteristics being unique depending on disease status (Rasmussen et al. 
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2017b; Ye et al. 2017). A powerful tool was also proposed to advance the search for an Aβ 
species that can be targeted for the treatment of AD (Rasmussen et al, in preparation). These 
findings have significantly added to our understanding of AD and will undoubtedly provide a 
platform for further investigations into this devastating disease. 
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The molecular architecture of amyloids formed in vivo can be
interrogated using luminescent conjugated oligothiophenes (LCOs),
a unique class of amyloid dyes. When bound to amyloid, LCOs yield
fluorescence emission spectra that reflect the 3D structure of the
protein aggregates. Given that synthetic amyloid-β peptide (Aβ) has
been shown to adopt distinct structural conformations with different
biological activities, we asked whether Aβ can assume structurally
and functionally distinct conformations within the brain. To this
end, we analyzed the LCO-stained cores of β-amyloid plaques in post-
mortem tissue sections from frontal, temporal, and occipital neocor-
tices in 40 cases of familial Alzheimer’s disease (AD) or sporadic
(idiopathic) AD (sAD). The spectral attributes of LCO-bound plaques
varied markedly in the brain, but the mean spectral properties of the
amyloid cores were generally similar in all three cortical regions of
individual patients. Remarkably, the LCO amyloid spectra differed
significantly among some of the familial and sAD subtypes, and be-
tween typical patients with sAD and those with posterior cortical
atrophy AD. Neither the amount of Aβ nor its protease resistance
correlated with LCO spectral properties. LCO spectral amyloid pheno-
types could be partially conveyed to Aβ plaques induced by experi-
mental transmission in a mouse model. These findings indicate that
polymorphic Aβ-amyloid deposits within the brain cluster as clouds of
conformational variants in different AD cases. Heterogeneity in the
molecular architecture of pathogenic Aβ among individuals and in
etiologically distinct subtypes of AD justifies further studies to assess
putative links between Aβ conformation and clinical phenotype.
Alzheimer | amyloid | neurodegeneration | prion | strains
Despite a common origin in the structural corruption and ac-cumulation of specific proteins, the clinical and pathological
phenotype of Alzheimer’s disease (AD) exhibits conspicuous vari-
ability within and among patients (1–4). The amyloid cascade hy-
pothesis posits that the seminal event in the pathogenesis of AD is
the misfolding and aggregation of the amyloid-β peptide (Aβ) (5, 6).
In vitro investigations have found that Aβ can aggregate into diverse
amyloid structures that can impose their conformational charac-
teristics onto naive synthetic forms of the protein (7, 8). In Aβ
precursor protein (APP)-transgenic mouse models, polymorphisms
of aggregated Aβ have been demonstrated that subsequently could
be propagated to naive and susceptible host mice (9–11).
Recent work in humans suggests that Aβ can aggregate into
structural variants with distinct pathobiological traits. One such
study used extracted fibrils from AD brains to seed the aggre-
gation of synthetic Aβ in vitro. The resulting synthetic descen-
dants of aggregated Aβ from brain samples provided indirect
evidence for structural heterogeneity of Aβ among AD brains; in
addition, the findings suggested that Aβ assumes a single, dom-
inant conformation within a given brain (12, 13). Another in-
vestigation has shown that the biophysical features of aggregated
Aβ differ significantly in patients with rapidly progressive AD
compared with those with normally progressive disease, indica-
tive of distinct molecular structures of Aβ (14). In an exceptional
example of Aβ aggregate structural variation in AD, a patient
was described as having an extraordinarily high Aβ burden but
a paucity of high-affinity Pittsburgh compound B (PiB) bind-
ing sites (15). More recently, X-ray microdiffraction analysis of
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individual AD brain tissue samples indicated that the amyloid
arrangement of Aβ is polymorphic within and among plaques (16).
Morphologically at the light-microscopic level, it is well
documented that amyloid plaques in AD brains present with
phenotypic variation that typically ranges from diffuse to dense-
cored plaques (17–24). How such morphotypes are linked to the
molecular conformation of the amyloid has not been established.
The characterization of amyloid has been facilitated by a new
class of dyes known as luminescent conjugated oligothiophenes
(LCOs; or luminescent conjugated polythiophenes) (25, 26).
LCO dyes bind to the repetitive cross–β-sheet structures of am-
yloid fibrils and display spectral differences based on the twisting
of the flexible LCO backbone (25, 27). Additionally, it was found
that certain LCOs compete with a Congo red analog (X-34) for
binding to recombinant Aβ-amyloid fibrils as well as AD brain-
derived Aβ, but they do not compete for the PiB binding site
(28). It has been demonstrated that LCOs can detect molecular
differences in Aβ plaque structure in different APP-transgenic
mouse models (10), and in Aβ aggregated in vitro at different
stages of fibrillization (25, 29, 30).
We hypothesized that the phenotypic and histopathological
variability of AD results, at least in part, from variation in the
molecular architecture of aggregated Aβ. To this end, we used
LCOs and biochemical analyses to evaluate the variation and
structural properties of amyloid in the plaques of patients with
AD from different etiological backgrounds [familial forms;
sporadic forms, including the posterior cortical atrophy (PCA)
variant of AD (PCA-AD); and a unique PiB-negative AD case].
Our results provide evidence for the existence of heterogeneous
Aβ-amyloid structures that cluster as clouds across different pa-
tients with AD while encoding conformational characteristics
that can be biologically propagated.
Results
Spectral Characteristics of Plaque Amyloid in AD Brains.We evaluated
plaque amyloid in tissue sections from a cohort of patients with
AD of various etiologies, including familial mutation carriers for
APP (V717I) and PSEN1 (A431E, F105L, and E280A), as well as
cases of typical sporadic AD (sAD) and sporadic PCA-AD (Table
S1). A double-stain combination with two LCOs, quadro-formyl
thiophene acetic acid (qFTAA) and hepta-formyl thiophene ace-
tic acid (hFTAA) (29, 30) (Methods), was used to label amyloid
plaques in fresh-frozen brain sections. Subsequently, the dense
(congophilic) cores of amyloid plaques were spectrally analyzed
for fluorescence emission characteristics (Figs. S1 and S2). Three
brain regions, the midtemporal gyrus (temporal), pericalcarine
gyri (occipital), and midfrontal gyrus (frontal), were investigated
for each patient (Fig. 1A). Preliminary visual inspection under
the fluorescence microscope revealed obvious variation in plaque
appearance even within a tissue section (Fig. 1B).
To determine how the molecular structure of plaque amyloid
varies among brains and brain regions, the mean emission spectra
were calculated for all plaques in each brain region of all subjects.
Pairwise comparisons between individual patients were then per-
formed using a Euclidean distance calculation (Fig. 1 C and D).
This analysis revealed that the spectral signatures of plaque amy-
loid in familial APP V717I and PSEN1 A431E mutation carriers
were most different from the other groups (Fig. 1C). Statistical
analysis of the ratio of the emission peaks for qFTAA (502 nm)
and hFTAA (588 nm) in individual plaque cores confirmed that
the APP V717I and PSEN1 A431E groups were significantly dif-
ferent from most other groups (Fig. 1E). A difference was also
found between sAD and PCA-AD cases (Fig. 1E). Of note, how-
ever, was the striking variability within the sAD group (Fig. 1 C and
E), with one of the samples with a high LCO spectral ratio being a
previously described case with reduced high-affinity binding of PiB
(Fig. 1 C and E).
To further interrogate the variability in LCO spectra among
the groups, all data points from the analysis based on the cor-
relation of fluorescence intensity at 502 nm and 588 nm were
examined (Fig. 1F). Again, the spectral signatures of plaque
amyloid in the different patient groups segregated into notice-
able clouds that partially overlapped each other (Fig. 1F).
Amyloid Plaque Spectral Characteristics Compared with Other
Metrics. To determine whether the results from the LCO spec-
tral analysis of plaques could be explained by factors that affect
amyloid deposition in the brain, LCO ratios were related to
apolipoprotein E (ApoE) genotype, subject age at death, and
postmortem interval (PMI) (Fig. 2). Only sAD and PCA-AD
samples were used to remove obvious confounding effects that
the familial mutations might have on the comparison (e.g.,
younger mean age at death). No correlation was found between
spectral ratio and ApoE status or subject age at death (Fig. 2 A–
C). The correlation found between the spectral ratio and the
PMI disappeared when sAD cases and PCA-AD cases were
analyzed separately, reflecting the overall longer PMI for the
PCA-AD samples (Fig. 2C). Thus, ApoE, age at death, and PMI
are not crucial factors for the observed LCO spectral differences.
To assess whether the LCO results are related to the total Aβ
load or the deposited Aβ species, Aβ was analyzed biochemically
(Fig. S2). Overall, samples from the PSEN1 A431E group had
higher Aβ levels than all other groups. The ratio of Aβ42/40 was
higher in the APP V717I familial mutation carriers compared
with the PSEN1 mutation carriers (Fig. S2). Neither the amount
of Aβ nor the Aβ42/40 ratio differed significantly across the three
neocortical regions; furthermore, the LCO spectra were not
significantly associated with either total Aβ or the Aβ42/40 ratio
when the analysis was confined to sAD and PCA-AD samples
(Fig. 2 D and E).
Proteinase K (PK) resistance has been linked to pathogenic
conformations of Aβ in mouse models and AD brains (11, 31,
32). To determine whether the LCO spectral signatures of the
plaque cores are associated with protease sensitivity, the re-
sistance of aggregated Aβ to proteolysis over time was evaluated
(Fig. S2). No differences among patient groups were observed
(Fig. S2). Furthermore, when only sAD and PCA-AD cases were
considered, there was no significant correlation between the
plaque spectral ratio and Aβ PK resistance (Fig. 2F).
Amyloid Plaque Spectral Characteristics Are Transmissible to Experimental
Mouse Models. We next asked whether the LCO spectral properties
of amyloid plaques can be propagated in vivo by the prion-like
process of molecular conformational templating. To this end,
cortical extracts from AD groups showing the most distinct LCO
spectra, namely, APP V717I, PSEN1 A431E, and sAD, in addition
to the unique PiB-negative sAD case, were injected into the hip-
pocampus of young APP23-transgenic mice (Fig. 3). APP23 mice
were used for this analysis because they have recently been char-
acterized in a seeding activity bioassay in which the precise bi-
ological activity of brain extracts was assessed (33). Before
injection, all extracts were pooled for each AD group and the Aβ
concentration was adjusted to 7.5 pg/μL. Since we found that the
LCO spectral characteristics of plaques did not differ significantly
among the three brain regions, we arbitrarily chose temporal
cortical samples as the source of Aβ seeds.
Inoculated APP23 mice were analyzed 6 mo after injection
(Fig. 3A). In all mice, Aβ deposition was induced in the hippo-
campus (primarily the dentate gyrus) as reported previously (9,
33). While this regional pattern of induction was not discernibly
different among the groups, the amount of induction showed
remarkable differences, with mice injected with APP V717I and
typical sAD extracts manifesting at least twice as much induced
Aβ deposition as mice injected with material from PSEN1 A431E
donors or from the PiB-refractory sAD donor (Fig. 3 A and B).
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Strikingly, when brain sections from the recipient mice were
stained using the same LCO protocol as that used for the hu-
man tissue (Fig. 1), quite remarkable differences in the emission
spectra of individual plaque cores were observed (Fig. 3A). The
mean emission spectra of all seeded hippocampal plaque cores
were computed for each injected mouse, and a Euclidean distance
calculation was applied to determine differences (Fig. 3C). Similar
to the LCO spectral patterns in plaques from the human donors,
seeded amyloid in the PSEN1 A431E-injected mice was most
different from that in the sAD groups, albeit with more variation
(Fig. 3 C and D). For statistical comparison of the experimental
groups, the 502-nm/588-nm spectral ratio was calculated for each
plaque core, and the mean ratios for each injected mouse were
computed (Fig. 3 D and E). The spectral ratios in the different
groups of seeded host mice displayed relatively similar patterns to
those in the donor humans (compare Figs. 1E and 3E); the group
difference was statistically significant between PSEN1 A431E- and
sAD-seeded mice, but the other group differences did not reach
statistical significance. The amount of induced Aβ deposition did
not correlate with the spectral ratio, suggesting these two factors
are independent (Fig. 3F). As with the human tissue, all plaque
cores analyzed in the mice were plotted based on the fluorescence
intensity at 502 nm against 588 nm (Fig. 3G). The plaques in
seeded mice occupied similar clouds within an injection group,
although these clouds showed more overlap in the injected mice
than in the original human tissue (Fig. 1), suggestive of differential
host–agent interactions (9).
Discussion
The extraordinary phenotypic variability of AD (1–3) currently
defies explanation. It is likely that many factors are involved, in-
cluding the age at disease onset, location of the initial abnor-
malities in the brain and their pattern of spread, the inflammatory
response to the lesions, and the presence of comorbid conditions.
The present findings support growing evidence that the hetero-
geneity of AD may also be influenced by the heterogeneous mo-
lecular architecture of misfolded Aβ in the brain.
Using synthetic Aβ that was aggregated in vitro, multimeric Aβ
assemblies have been shown to assume diverse tertiary and
quaternary structures (13, 34–37). These findings have greatly
augmented our understanding of Aβ fibril structure, but their
relevance to the pathobiology of Aβ in vivo, in the native disease
Fig. 1. Subtypes of AD display distinguishable clouds
of amyloid conformational variants. (A) Combination
of two LCOs, qFTAA and hFTAA, was used to stain Aβ
plaques in three different neocortical regions (tem-
poral: midtemporal gyrus, T; occipital: pericalcarine
gyri, O; frontal: midfrontal gyrus, F) of postmortem
brain tissue from familial AD (APP V717I, PSEN1
A431E, PSEN1 F105L, and PSEN1 E280A), typical sAD,
and sporadic PCA-AD cases. (B) Shown is an LCO-
stained section of the temporal cortex from a patient
with sAD (AD16; also patient information in Table S1).
Note that a variety of different fluorescence emission
patterns are present in a single brain sample. (Scale
bars: Left, 200 μm; Right, 20 μm.) (C and D) Plaques
were randomly selected, and for each plaque core,
the fluorescence intensity was measured at 22 wave-
lengths to produce a continuous fluorescence spec-
trum (40–60 plaques were analyzed per region for
each brain sample; also Fig. S1). Each line in D rep-
resents the mean spectrum for a particular brain area
in all patients in a given subgroup. A heat map
depicting the difference of Euclidean distances be-
tween the mean spectra (of all 22 fluorescence mea-
surements) for brain regions of individual patients is
shown in C. Larger and more darkly colored circles
represent more dissimilar spectra. The labels repre-
sent patient numbers with the temporal, occipital,
and frontal regions repeating as sets of three (from
top to bottom). Note the variability within the sAD
group, with some regions yielding emission spectra
more similar to those of the familial groups (for AD2,
only temporal and occipital cortex tissue was avail-
able for analysis). (E) For statistical analysis, the fluo-
rescence intensity at 502 nm and 588 nm (which
represent the fluorescence emission peaks of qFTAA
and hFTAA, respectively; Fig. S1C) was analyzed for
each region of each patient. Two-way ANOVA (brain
region × AD subtype) revealed a significant effect for
subtype [F(5,101) = 33.07, P < 0.0001], but not for brain
region [F(2,101) = 0.0681, P = 0.9343] or interaction
between region and subtype [F(10,101) = 0.7829, P =
0.6451]. Tukey’s multiple comparisons revealed sig-
nificant differences between APP V717I vs. PSEN1
E280A, sAD and PCA-AD; PSEN1 A431E vs. PSEN1
F105L, PSEN1 E280A, sAD and PCA-AD; PSEN1 F105L
vs. PSEN1 E280A, sAD and PCA-AD; and sAD vs. PCA-
AD (all probabilities at least P < 0.05). An exceptional sAD case, AD34 (denoted by arrows in C and E), is a previously described case with reduced high-affinity
binding of the PiB radioligand (15). Error bars represent the SEM. (F) Scatter plot of all plaques analyzed using fluorescence at 588 nm vs. 502 nm per AD subgroup
reveals that plaque spectral properties within the AD subgroups occupy distinct clouds, which overlap between AD subgroups.
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state, remains uncertain (38). For instance, in most cases, these
experiments involved the analysis of a single isoform of Aβ, ei-
ther 40 aa or 42 aa long, whereas there are multiple isoforms,
fragments, and posttranslational modifications of Aβ in the living
brain (39, 40).
Tycko and coworkers (12, 13) have demonstrated that Aβ
derived from different cases of AD is able to induce synthetic Aβ
to assemble into corresponding structural “strains,” and the au-
thors suggest that a single Aβ structure predominates in a par-
ticular AD brain. Our observations generally support the concept
of a predominant, case-specific Aβ strain in that the mean
LCO spectral emission of plaque cores (where the Aβ adopts an
amyloid conformation) was similar in different cortical regions
of each patient, regardless of the AD subtype. However, direct
microscopic analysis of individual plaque cores with LCOs
allowed us to determine that minor populations of Aβ aggregates
with different molecular architectures also are present within a
given AD brain. We therefore speculate that the presence of
these structural variants in other investigations (12, 13) may have
been masked by the conformational selection and in vitro pro-
pagation of a dominant strain in preparation for the NMR ana-
lysis. In support of this possibility, and in agreement with our
findings, X-ray microdiffraction analysis has revealed structural
polymorphism among amyloid plaques within the same tissue
section (16).
In light of the intra- and interindividual variability in the LCO
spectral characteristics of plaque amyloid, it is remarkable that
we still found differences among patient subgroups, particularly
between some of the familial AD and sAD cases (note that the
familial AD mutations in the present study do not change the Aβ
sequence). Neuropathological analyses also have revealed dif-
ferences in plaque morphotypes between some familial AD
mutations and sAD (18, 20, 23). However, while these observa-
tions were made on Aβ-immunostained plaques, our LCO-based
spectral analysis was confined to the core of the plaque, and thus
to Aβ in the amyloid conformation.
We were somewhat surprised to observe differences in the
amyloid spectral characteristics between typical patients with
sAD and patients with the PCA variant of AD. Both the regional
distribution of amyloid and the clinical phenotype are different
in PCA-AD and sAD (41). A previous NMR analysis did not
indicate molecular structural differences between PCA-AD and
sAD (13), but, as noted above, the analysis could have been
confounded by conformational selection of Aβ species best
suited for the seeded in vitro growth of fibrils. The clinicopath-
ological distinctiveness of PCA-AD appears to result, in part,
from a disease-specific site of origin and/or pattern of Aβ dis-
semination (41), but our findings indicate that the molecular
architecture of misfolded Aβ may also play a role. Similarly, in a
rapidly progressive subtype of AD, there is biochemical evidence
for increased conformational heterogeneity of Aβ42 (14), and a
recent NMR study using seeded growth of synthetic Aβ fibrils
from brain-derived material supports this finding (13).
In the present study, the LCO spectral characteristics of amy-
loid in plaques did not correspond in a consistent way to the PK
resistance or the abundance of the two major Aβ species (Aβ40
and Aβ42) in tissue homogenates. One possible explanation for
this is that the spectral analysis and biochemical tests do not probe
identical populations of Aβ [i.e., the amyloid core (LCOs) vs. the
total pool of aggregated Aβ (biochemistry)]. Another possibility is
that variation in amyloid structure revealed by the LCO spectral
analysis is more sensitive at identifying subtle differences that
biochemical analyses currently are unable to detect. Elucidation of
the mechanisms underlying the architectural variability of Aβ in
plaques could reveal pathogenically important targets for the de-
velopment of personalized treatments for AD.
LCO binding and spectra are dependent on the orientation,
side-chain interactions, and packing of amyloid fibrils, and the
ability of LCOs to recognize amyloid features in protein pathol-
ogies has been well characterized (25). These ligands thus are
exquisitely sensitive indicators of molecular architectural differ-
ences in proteopathic fibrils, for example, the strain-like diversity
of prion protein aggregates (42). In recent studies, it has been
shown that the arrangement and packing of Aβ-amyloid fibrils
influence the spectral output of the LCOs, especially when the
ligands are used in combination (29, 30, 43). Since LCO spectra
indicate the presence of different structural conformations of Aβ,
we predicted from previous experiments that these properties
should be transmissible to susceptible hosts (44). Our studies in
APP-transgenic mice confirm that Aβ-rich brain extracts from
different subtypes of AD seed Aβ deposits that are correspond-
ingly differentiable using LCOs. The LCO spectral traits of amy-
loid in the seeded transgenic mice did not perfectly mirror those of
the human donor tissue; however, this is expected because both
Fig. 2. Spectral properties of LCO-labeled amyloid plaques are not
explained by ApoE genotype, patient age, PMI, or Aβ biochemistry. (A) LCO
spectral ratio of fluorescence at 502 nm and 588 nm separated into ApoE
genotype subgroups (mean of the three regions; Fig. 1E; only subjects with
sAD and PCA-AD were used to remove the confounding effects of the fa-
milial mutations on the data; orange triangles, sAD; cyan diamonds, PCA-
AD). The Mann–Whitney test was used to determine significance between
ApoE 3/3 vs. 3/4 cases (P = 0.4221). Error bars represent the SEM. (B) LCO
spectral ratio vs. patient age. Nonparametric Spearman correlation: P = 0.38.
(C) LCO spectral ratio vs. PMI. Nonparametric Spearman correlation: P =
0.29 for PCA-AD and P = 0.32 for sAD. (D and E) LCO spectral ratios vs. ELISA
measurements (mean of all brain regions) of Aβ 40 + 42 and the Aβ42/
40 ratio (Aβ measurements are shown in Fig. S2). Nonparametric Spearman
correlation analysis yielded P = 0.26 and P = 0.81, respectively. (F) LCO
spectral ratio vs. Aβ remaining after 1 h of digestion with PK (mean of all
brain regions). Nonparametric Spearman correlation: P = 0.78. Detailed re-
sults for PK digestion are shown in Fig. S3.
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the agent and host influence the propagation of Aβ and the
characteristics of the resulting deposits (9). In addition, the mice
were seeded with extracts of brain tissue, which may have a seed
composition that differs from that in the plaque cores. The exis-
tence of LCO spectral clouds that only partially recapitulate those
of the AD donors thus may reflect the composition of seeds in the
donor extract as well as the Darwinian selection of different Aβ
strains in the host mice (45).
The spectral properties of LCOs bound to plaques change as
APP-transgenic mice grow older, suggestive of age-related con-
formational rearrangement of the Aβ (30). Thus, it is possible
that the spectral variation of plaques in individual patients with
AD at least partially reflects the presence of plaques of different
ages. The AD brains analyzed in the present study were all from
patients with end-stage disease, at which point amyloid, per se,
may no longer be the primary driver of the disease (46). Nev-
ertheless, the deposited amyloid shows remarkable LCO spectral
variability among patients with sporadic end-stage AD. Fur-
thermore, the LCO spectral signals detected within an individual
brain, although generally similar in the three cortical regions,
constitute a cloud of variable emission spectra. It is possible that
the composition of the amyloid may be more complex late in the
pathogenic process than at earlier time points. If so, the LCO
spectra might reveal more clearly differentiable disease patterns
in the earlier stages. Analysis of incipient amyloid plaques in
persons who died of other causes before the onset of AD
symptoms will be informative in this regard. Finally, it will be
important to establish the relationship between the variant mo-
lecular structure of plaque cores and the pathobiologically po-
tent oligomeric forms of Aβ (31, 47).
The present findings have several implications for diagnostics
and treatment. Variations in amyloid structure are likely a com-
plicating factor when determining the distribution and severity of
Aβ deposition by PET imaging in patients with AD, as demon-
strated by an unusual case of AD with very high Aβ levels in the
brain but negligible high-affinity binding of PiB (15). We found
that the plaque cores in this case displayed an LCO spectral pattern
that differed from that of most other sAD cases. If antibody
binding to Aβ is similarly influenced by the molecular architecture
of the misfolded protein, it is conceivable that a particular mono-
clonal antibody might fail to recognize the full range of Aβ ag-
gregates that can arise within a brain and among different patients.
Thus, it may be advantageous to use multiple antibodies to create a
“polyclonal” mixture for treatment of Aβ pathology. Finally, future
work should investigate the therapeutic potential of LCOs for AD
and other proteopathies, as has been shown for prion disease (27),
and, additionally, determine the feasibility of using LCOs to ex-
amine Aβ aggregates in bodily fluids such as cerebrospinal fluid
and blood to augment the personalized diagnosis of AD.
Methods
Patient Samples. Fresh tissue samples were obtained from the midtemporal
gyrus (temporal), pericalcarine gyri (occipital), and midfrontal gyrus (frontal)
of 40 clinically and pathologically diagnosed AD cases (Table S1). The tissues
were acquired under the proper Institutional Review Board protocols from
the Tübingen Review Board for the work in the Queen Square Brain Bank at
University College London samples (202/2016BO2), the Emory University
Alzheimer’s Disease Research Center to do the work on these samples (IRB
00045782), and the University of Antioquia, Medellin, Colombia (09-10-232).
Informed consent was given by families (see SI Methods for details).
Fig. 3. Variant conformations of aggregated Aβ
can be induced by exogenous seeding in APP-
transgenic mice. (A) Seeding extracts were prepared
from the middle temporal gyrus of pooled (n = 3)
brain samples from human APP V717I, PSEN1 A431E,
sAD [AD15, AD16, and AD24; patients collected in
the same year at the same site (Emory University)]
and a single PiB-refractory sAD case (AD34) (Fig. 1
and Table S1). Aβ concentrations of the seeding
extracts were adjusted to 7.5 pg/μL (Methods). Ex-
tracts were injected into young (4-mo-old) female
APP23 mice [APP V717I (n = 6), PSEN1 A431E (n = 7),
sAD (n = 8), and PiB-negative (neg.) sAD (n = 6)].
Brains of recipient mice were analyzed 6 mo after
injection. Induced Aβ deposition in the hippocampus
was stained with a polyclonal Aβ antibody (Top) or
the LCO double-staining protocol (Bottom). (Scale
bars: Top, 200 μm; Bottom, 50 μm.) (B) Stereological
quantification of Aβ-immunostained area in the
hippocampus. The Kruskal–Wallis test followed by
Dunn’s multiple comparison test revealed significant
differences in the degree of induction between APP
V717I vs. PSEN1 A431E (P < 0.05) donors, PiB-neg.
sAD vs. APP V717I donors (P < 0.001), and PiB-neg.
sAD vs. sAD donors (P < 0.01). Error bars represent
SEM. (C) Heat map of the Euclidean distance be-
tween LCO spectra calculated for each mouse (de-
tails are provided in Fig. 1). Larger and more darkly
colored circles represent more dissimilar spectra. (D)
Mean LCO fluorescence spectra of induced plaque
cores for mice injected with different human ex-
tracts (20–30 plaques were analyzed per mouse;
details are provided in Fig. 1). (E) For statistical
analysis, the mean ratio of the fluorescence intensity
at 502 nm and 588 nm was calculated for each
mouse. The Kruskal–Wallis test followed by Dunn’s
multiple comparison test revealed significantly different spectral signatures in plaques seeded by PSEN1 A431E vs. sAD brain extracts (P < 0.05). Error bars
represent the SEM. (F) Amount of Aβ induction did not correlate with the LCO spectral ratio of the induced amyloid (nonparametric Spearman correlation, P =
0.9687). (G) Scatter plot of LCO fluorescence spectra emitted by all plaques analyzed in seeded mice demonstrates an overall preservation of clustering among
the groups, although the group differences were less distinct compared with plaque spectra in the original human donor samples (Fig. 1).
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LCO Staining Spectral Analysis. Two LCO variants, qFTAA and hFTAA,were used
to stain fresh-frozen tissue (30). Amyloid plaques were randomly chosen, and
continuous emission spectra were acquired (Figs. S1 and S2). Only the dense
cores of plaques were analyzed. Details are provided in SI Methods.
Aβ Quantification, Mass Spectrometry, and PK Digestion. For Aβ quantification,
human tissue was extracted with 70% formic acid. Extracts were also analyzed
by targeted mass spectrometry for Aβ (48). PK digestion was carried out on
fresh tissue at 37 °C for 0, 1, 2, and 4 h and analyzed with Aβ immunoblots.
Details are provided in SI Methods.
In Vivo Inoculations of the Mice. Seeding extracts were generated from the
middle temporal gyrus (33). Pooled extracts [APP V717I (AD1–3), PSEN1 A431E
(AD4–6), and typical sAD (AD15, AD16, and AD24)] and the distinct PiB-negative
sAD case (AD34) (Table S1) were adjusted to the same Aβ concentration. In-
trahippocampal injections were done in 4-mo-old APP23 mice (49). After 6 mo
of incubation, brain sections were Aβ-immunostained and quantified (50, 51).
Sections were also stained with the LCOs. All mouse experiments were ap-
proved by the local animal care and use committee in Baden-Württemburg,
Germany (Regierungspräsidium Tübingen). Details are provided in SI Methods.
Statistical Analysis. GraphPad Prism (v.5) was used for statistical analyses.
R (v. 3.3.2) was used for Euclidean distances. Details are provided in SIMethods.
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SI Methods
Patient Samples. Tissue samples were obtained from the mid-
temporal gyrus (temporal), pericalcarine gyri (occipital), and mid-
frontal gyrus (frontal) of 40 clinically and pathologically diagnosed
AD cases (Table S1). Among them, 13 familial cases (AD 1–13) had
the following mutations: V717I in APP, three cases; A431E in
PSEN1, three cases; F105L in PSEN1, two cases; and E280A in
PSEN1, five cases. The remaining 27 cases had a typical sporadic
(idiopathic) etiology (AD14–34) or a sporadic PCA variant of AD
(AD35–40). The samples were obtained from four different sources,
the Emory University Alzheimer’s Disease Research Center; the
Dementia Laboratory, Department of Pathology and Laboratory
Medicine, Indiana University School of Medicine; the Queen
Square Brain Bank at University College London; and the Institute
of Medical Research, Faculty of Medicine, University of Antioquia,
Medellín, Colombia. Human postmortem tissues were acquired
under proper Institutional Review Board protocols with consent
from families.
LCO Staining and Immunohistochemistry on Patient Samples. Two
different LCO variants, qFTAA and hFTAA, were used for de-
tection and analysis of amyloid pathology. Fresh-frozen human
tissue was cut into 12-μm-thick sections on a cryotome, dried at
room temperature (RT) overnight, and stored at −80 °C. Tissue
was thawed, air-dried, and then double-stained with qFTAA and
hFTAA (2.4 μM qFTAA and 0.77 μM hFTAA in PBS) similar to
a previously described protocol (30). Sections were incubated for
30 min at RT in the dark.
Immunohistochemistry was performed using a polyclonal pri-
mary antibody directed against Aβ (CN6) as previously described
(50). Staining with Congo red and Thioflavin-S for amyloid was
conducted according to standard protocols.
Spectral Analysis. Spectra were acquired on a Zeiss LSM 510
META confocal microscope equipped with an argon 458-nm laser
for excitation and a spectral detector (Carl Zeiss MicroImaging
GmbH). A 40× oil-immersion objective (1.3 N.A.; Zeiss) was used
for spectral imaging of Aβ-amyloid cores. Continuous emission
spectra were acquired from 470 to 695 nm. The amyloid plaques
were randomly chosen, and three regions of interest were mea-
sured in the core of each deposit (Figs. S1 and S2). Only the dense
cores of plaques were analyzed. Other types of Aβ deposits (dif-
fuse plaques, intracellular Aβ, and cerebral amyloid angiopathy)
were excluded. Care was taken to avoid interference of lipofuscin-
induced autofluorescence with LCO signals; the use of spectral
imaging allowed us to distinguish between the distinct LCO fluo-
rescence spectrum and unwanted autofluorescence.
A total of 15 to 25 Aβ plaque cores were measured in each
region, totaling 45–60 plaques per patient. After the spectral
measurements, all emission spectra were normalized to their
respective maxima. The mean spectral signature of each plaque
core was calculated before averaging the values for each brain
area in each patient. The ratio of the intensity of emitted light at
the blue-shifted peak (502 nm) and red-shifted peak (588 nm)
was used as a parameter for spectral distinction of different Aβ
deposits. The peaks of the spectra were selected to maximize the
spectral distinction.
For the heat map of Euclidean distance calculation, the average
spectrum from 470 nm to 695 nm was calculated for each brain
region. Different spectra were then compared in two samples
using the following Euclidean distance calculation:
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiX695nm
470nm
ðADx470nm −ADy470nmÞ2 + . . . + ðADx695nm −ADy695nmÞ2
vuut .
In short, the “square-root of the sum-of-squared-differences”
was calculated between two samples using the 22 wavelength
measurements of fluorescence intensity. This pairwise calcula-
tion was completed for every sample pair used in the study. The
output of these calculations is then displayed as a heat map,
with larger and more darkly colored circles representing a large
Euclidean distance (more different emission spectra). This heat
map represents the comparison between samples for the entire
emission curve. Further statistical comparisons between sam-
ples were undertaken using the ratio of the fluorescence inten-
sity at two wavelengths (502 nm/588 nm) representing the peaks
of fluorescence for the two dyes used in this study. The Euclid-
ean distance calculation and the heat map were generated in
R (v. 3.3.2).
ECL-Based Multiarray for Aβ Quantification. Human tissue was ho-
mogenized in PBS (10% wt/vol) using the Precellys system with a
2 × 20-s cycle at 5,500 rpm (Precellys24 Homogenizer, EQ03119-
200-RD000.0, Bertin Instruments). Samples were then extracted
with 70% formic acid (final concentration) and centrifuged at
25,000 × g for 60 min at 4 °C. Supernatants were collected and
neutralized with buffer (1 M Tris base, 0.5 M Na2NPO4, 0.05%
NaN3) before analysis with a V-PLEX Peptide Panel 1 (6E10) Aβ
kit from Meso Scale Discovery following the manufacturer’s
specifications.
PK Digestion. Samples homogenized with the Precellys system de-
scribed previously were centrifuged at 800 × g for 5 min at 4 °C, and
the supernatant was collected. Protein concentrations were de-
termined using a bicinchoninic acid total protein kit, and samples
were then digested with 1 μg of PK/3 μg of protein at 37 °C.
Samples were collected for analysis at 0, 1, 2, and 4 h and stopped
with 2 mM PMSF. Samples were heated to 70 °C for 10 min in
LDS sample buffer (Invitrogen), loaded onto 4–12% Bis-Tris
precast gels, and run at 125 V for 44 min. Gels were transferred
onto nitrocellulose and subsequently boiled at 95 °C for 5 min in
PBS. Blocking was achieved with 4% skim milk in PBS with 0.05%
Tween-20 for 60 min at RT. Membranes were probed with anti-
body 6E10 (1:5,000) overnight at 4 °C and then incubated with a
goat anti-mouse secondary antibody (1:30,000) for 60 min. De-
velopment was carried out with Dura Extended Duration Substrate
(Pierce) before exposure on Hyperfilm ECL film (Amersham).
Band intensities were quantified using ImageJ software (NIH).
Mass Spectrometry.Human tissue was homogenized in PBS (10%
wt/vol) using the Precellys system with a 2 × 20-s cycle at
5,500 rpm (Precellys24 Homogenizer, EQ03119-200-RD000.0,
Bertin Instruments). Samples were then extracted with 70%
formic acid, centrifuged at 25,000 × g for 60 min at 4 °C, and
dried in a speedvac. The samples were reconstituted in 200 μL of
formic acid for 30 min and then neutralized to pH 7 using 0.5 M
Tris. Aβs were then immunoprecipitated using Aβ-specific anti-
bodies [antibodies 6E10 and 4G8 (Signet Laboratories)] coupled
to magnetic Dynabeads M-280 Sheep Anti-Mouse IgG (Invi-
trogen) as described previously (48). Mass spectrometry was
performed using a MALDI TOF/TOF instrument (UltraFleXtreme;
Bruker Daltonics). Analysis was completed as described
previously (48).
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In Vivo Inoculations.Given that the LCO spectral characteristics of
plaque cores did not differ among the three brain regions, we
prepared the donor inoculum from temporal cortical samples only.
Seeding extracts were generated from a 10% (wt/vol) homogenate
of the middle temporal gyrus using the Precellys system as de-
scribed above. The homogenates were subsequently centrifuged at
3,000 × g for 5 min at 4 °C. The supernatants were then collected
and stored at −80 °C. Quantification of Aβ in the extracts was
performed after formic acid extraction using the MesoScale
platform. Seeding extracts were pooled for the APP V717I (AD1–
3), PSEN1 A431E (AD4–6), and typical sAD (AD15, AD16, and
AD24) groups (Table S1), while the PiB-refractory case remained
distinct. All samples then were adjusted to the same total Aβ
concentration (7.5 pg/mL) using PBS as a diluent.
Predepositing 4-mo-old female APP23 mice (49) were injected
bilaterally (2.5 μL each) with seeding extracts from the APP
V717I (n = 6), PSEN1 A431E (n = 7), typical sAD (n = 8), and
PiB-negative sAD (n = 6) cases following anesthesia with ket-
amine/xylazine (100 mg/kg to 10 mg/kg of body weight). Injec-
tions were targeted to the hippocampus (anteroposterior, −2.5 mm;
left/right, ±2.0 mm; dorsoventral, −1.8 mm) and delivered with a
Hamilton syringe at a speed of 1.25 μL/min. The syringe was kept in
place for an additional 2 min and then slowly withdrawn. The
surgical incision then was closed, and the mice were closely mon-
itored until regaining consciousness. All experimental procedures
with the mice were carried out in accordance with the veterinary
office regulations of Baden-Württemberg (Germany) and ap-
proved by the local animal care and use committees (Regierung-
spräsidium Tübingen).
Histological Analysis of theMice.After 6 mo of incubation following
infusion of brain extracts, the mice were killed by deep anesthesia
(250 mg/kg ketamine and 25 mg/kg xylazine) and transcardial
perfusion with ice-cold PBS. The brains were immersion-fixed in
4% paraformaldehyde-PBS for 48 h and then cryoprotected in
30% sucrose-PBS. After snap-freezing in methyl butane, brains
were sectioned at 25-μm thickness on a freezing-sliding micro-
tome (Microm; Thermo Scientific) and collected in 12-well
plates (every 12th section was represented in a well) containing
cryoprotectant solution (35% ethylene glycerol and 25% glycerol
in PBS). Sections were immunostained for Aβ using either a
polyclonal antibody (discussed above) and Vectastain Elite ABC
kit (Vector Laboratories) (50) or the double-stain LCO protocol
outlined for the human tissue (discussed above).
The hippocampus (every 12th section) of each animal was
analyzed for the area occupied by Aβ-positive immunostaining
with stereological analysis on a video-microscopy system (Zeiss
Axioskop 2) equipped with a motorized x-y-z stage and Stereo
Investigator software (MicroBrightField) as previously described
(51). The area occupied by Aβ-positive staining was determined
using 2D sectors in a single focal plane (magnification of 20×/
0.45-N.A. objective) as sampling sites.
Statistical Analysis. To test normality, the D’Agostino–Pearson
omnibus normality test was used. For two-way ANOVA followed
by Tukey’s multiple comparisons test, data were logarithmically
transformed when not normally distributed. The nonparamet-
ric Spearman correlation or Kruskal–Wallis test followed by
Dunn’s multiple comparison test were used in all other analyses.
GraphPad Prism (v.5) was used for all statistical analyses.
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Fig. S1. Analysis of LCO-stained amyloid plaque cores. (A and B) Two representative images of the temporal cortical region of a sAD case (AD16) that was
stained with hFTAA and qFTAA. For each plaque core, three regions of interest (circle/cross symbols) were set and the fluorescence intensity was measured at
22 wavelengths. A plaque core with an emission peak in the blue spectrum is shown in A, whereas B shows a plaque core with an emission peak in the red
spectrum. For each plaque core, the mean was calculated from the three regions of interest. Diffuse plaques, cerebral amyloid angiopathy, and intracellular
aggregates were not included in this analysis. (Scale bars: 20 μm.) (C) For comparative illustration, the spectra of the single-LCO dyes hFTAA and qFTAA are
shown. Single staining with either hFTAA or qFTAA was performed on three different patients (AD17, AD20, and AD23), and the individual spectra were
calculated from 60 different plaques. qFTAA shows a peak around 500 nm, whereas hFTAA shows two peaks around 550 and 590 nm.
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Fig. S2. Double staining of LCOs combined with other amyloid markers. Tissue from a sAD case (AD17) was stained with hFTAA and qFTAA and in adjacent
sections with Congo Red (CR), Thioflavin-S (ThS), or the polyclonal Aβ antibody CN6. (A) Three blue-shifted plaques are shown with adjacent sections stained for
CR (Inset shows birefringence), ThS, or CN6. (B) Three red-shifted plaques are shown with adjacent sections stained for CR (Inset shows birefringence), ThS, or
CN6. No differences in staining between the blue- and red-shifted plaque (cores) were detected with CR, ThS, or the Aβ antibody. (Scale bars: 20 μm.)
Rasmussen et al. www.pnas.org/cgi/content/short/1713215114 4 of 6
	 72   
Fig. S3. Biochemical analysis of brain tissue from different AD subtypes. Levels of total Aβ40 + Aβ42 (A) and Aβ 42/40 ratio (B) for each patient (formic acid
extraction before 25,000 × g centrifugation) were assessed by ECL-based multiarray. Two-way ANOVA (brain region × subtype) revealed significantly different
levels of Aβ among AD subtypes [F(4,89) = 8.278, P < 0.0001], but no significant differences among brain regions [F(2,89) = 2.375, P = 0.0989]. No subtype × region
interaction was found [F(8,89) = 0.8558, P = 0.5568]. Tukey’s multiple comparisons test revealed significant differences in total Aβ between APP V717I vs. PSEN1
A431E and sAD; PSEN1 A431E vs. PSEN1 F105L, sAD, and PCA-AD (all probabilities at least P < 0.05). Two-way ANOVA also revealed significantly different Aβ42/
40 ratios in the AD subtypes [F(4,89) = 4.744, P = 0.0016], but no significant differences among brain regions [F(2,89) = 0.3785, P = 0.6860] or in the subtype ×
region interaction [F(8,89) = 0.2835, P = 0.9698]. Tukey’s multiple comparisons test revealed significant differences in the Aβ42/40 ratio between APP V717I vs.
PSEN1 A431E and PSEN1 F105L; PSEN1 A431E vs. sAD (all probabilities at least P < 0.05). (C–E) PK digestion of brain samples was used to determine protease
resistance of Aβ over time (0, 1, 2, and 4 h), expressed as the fraction remaining after digestion compared with the undigested sample. Brain regions were
analyzed individually. No significant differences were found among patient subtypes using two-way ANOVA (time × subtype) for the temporal [F(4,30) = 1.197,
P = 0.3325], occipital [F(4,30) = 2.080, P = 0.1083], or frontal [F(4,29) = 2.184, P = 0.0957] region. Significant differences for the time effect were seen in the
temporal [F(3,90) = 106.7, P < 0.0001], occipital [F(3,90) = 152.9, P < 0.0001], and frontal [F(3,87) = 134.5, P < 0.0001] regions. Interactions were not significant in the
temporal [F(12,90) = 1.351, P = 0.2049], occipital [F(12,90) = 1.211, P = 0.2877], or frontal [F(12,87) = 1.717, P = 0.0767] region. Note that PSEN1 E280A cases were not
included for biochemical analysis because fresh-frozen tissue samples were not available when other measurements were completed. (F) Mass spectrometry
analysis of the brain samples used for injections (Fig. 3) revealed that all samples contained Aβ1–42, Aβ4–42, and pGlu3–42, with APP V717I samples containing
additional Aβx–42 peptide species and patients with PSEN1 A431E and sAD harboring Aβ1–40. The PiB refractory case also had abundant Aβ1–40 as well as Aβ1–
38 in the tissue.
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Table S1. Patient information
Case Etiology Age, y Sex PMI, h ApoE status
AD1 APP V717I 45 M 4.0 n.a.
AD2 APP V717I 49 F 2.7 E3/3
AD3 APP V717I 54 F 5.3 E3/3
AD4 PSEN1 A431E 43 F 4.0 E3/3
AD5 PSEN1 A431E 47 n.a. n.a. E3/3
AD6 PSEN1 A431E 44 M n.a. E3/3
AD7 PSEN1 F105L 68 F 36.0 E2/3
AD8 PSEN1 F105L 67 F 8.0 E2/3
AD9 PSEN1 E280A 52 M 4.8 E3/3
AD10 PSEN1 E280A 42 F 6.5 E3/3
AD11 PSEN1 E280A 63 F 6.5 E3/3
AD12 PSEN1 E280A 63 M 3.8 E3/3
AD13 PSEN1 E280A 58 M 3.5 E3/3
AD14 sAD 80 F 25.8 n.a.
AD15 sAD 62 M 8.5 E2/3
AD16 sAD 81 F 17.7 E3/3
AD17 sAD 70 M 8.5 E3/3
AD18 sAD 81 F n.a. E3/3
AD19 sAD 62 F 6.0 E3/3
AD20 sAD 74 M 2.5 E3/3
AD21 sAD 54 M 5.5 E3/3
AD22 sAD 91 F 3.0 E3/3
AD23 sAD 81 M 4.0 E3/3
AD24 sAD 89 M 49.0 E3/4
AD25 sAD 64 M 9.0 E3/4
AD26 sAD 87 F 6.0 E3/4
AD27 sAD 58 F 6.0 E3/4
AD28 sAD 77 M 6.0 E3/4
AD29 sAD 88 M 9.0 E3/4
AD30 sAD 70 F 46.9 E3/3
AD31 sAD 67 M 28.6 n.a.
AD32 sAD 77 M 90.1 E4/4
AD33 sAD 76 F 26.8 n.a.
AD34* sAD 72 F 3.0 E3/4
AD35 PCA-AD 76 M 50.3 E3/3
AD36 PCA-AD 71 M 57.5 E3/4
AD37 PCA-AD 68 F 86.8 E3/4
AD38 PCA-AD 88 F 40.3 E3/3
AD39 PCA-AD 71 M 47.6 E3/3
AD40 PCA-AD 65 F 46.6 n.a.
F, female; M, male; n.a., information not available.
*PiB-negative sAD case: AD34.
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Abstract
Little is known about the extent to which pathogenic factors
drive the development of Alzheimer’s disease (AD) at different
stages of the long preclinical and clinical phases. Given that the
aggregation of the b-amyloid peptide (Ab) is an important factor
in AD pathogenesis, we asked whether Ab seeds from brain
extracts of mice at different stages of amyloid deposition differ
in their biological activity. Specifically, we assessed the effect of
age on Ab seeding activity in two mouse models of cerebral Ab
amyloidosis (APPPS1 and APP23) with different ages of onset and
rates of progression of Ab deposition. Brain extracts from these
mice were serially diluted and inoculated into host mice. Strik-
ingly, the seeding activity (seeding dose SD50) in extracts from
donor mice of both models reached a plateau relatively early in
the amyloidogenic process. When normalized to total brain Ab,
the resulting specific seeding activity sharply peaked at the
initial phase of Ab deposition, which in turn is characterized by a
temporary several-fold increase in the Ab42/Ab40 ratio. At all
stages, the specific seeding activity of the APPPS1 extract was
higher compared to that of APP23 brain extract, consistent with
a more important contribution of Ab42 than Ab40 to seed activ-
ity. Our findings indicate that the Ab seeding potency is greatest
early in the pathogenic cascade and diminishes as Ab increasingly
accumulates in brain. The present results provide experimental
support for directing anti-Ab therapeutics to the earliest stage of
the pathogenic cascade, preferably before the onset of amyloid
deposition.
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Introduction
The accumulation of amyloid in the brain parenchyma and vascula-
ture is a defining histopathological feature of Alzheimer’s disease
(AD) that begins at least a decade before clinical symptoms appear
[1–3]. In the AD brain, amyloid consists mainly of b-sheet-rich
amyloid-b peptide (Ab), a cleavage product of the Ab precursor
protein (APP). Ab is generated in various lengths, with the majority
ending at amino acid 40 or 42 (Ab40 and Ab42, respectively), and
the ratio of these two isoforms influences their pathobiology [4] as
well as the disease phenotype [5–7].
The misfolding and aggregation of Ab is thought to follow a
prion-like seeding mechanism [8]. In vitro, Ab self-assembles
into small nuclei (slow nucleation phase), which in turn act as
corruptive templates (seeds) to incite a chain reaction of protein
misfolding and multimerization. The subsequent aggregation then
yields polymeric fibrils (rapid growth phase) that are typical of
amyloid [8,9]. In vivo studies suggest that a similar seeding
mechanism drives cerebral b-amyloidosis [10]. Injection of Ab-
rich brain extracts or synthetic, pre-aggregated Ab initiates and
accelerates Ab plaque deposition in APP transgenic (tg) mice
[11–14].
Given the importance of Ab seeds in the initiation and progres-
sion of the amyloid cascade, we asked whether Ab from brain
extracts of mice at different stages of the disease process differs in
its seeding activity. Surprisingly, in two mouse models of cerebral
b-amyloidosis, we found that the seeding potency per Ab molecule
(specific seeding activity) is greatest early in the pathogenic
cascade and declines with the deposition of Ab in brain. This
observation provides experimental support for the view that treat-
ments for AD are likely to be most effective at the very beginning
of the long preclinical phase that precedes the emergence of symp-
toms [15].
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Results and Discussion
The trajectory of cerebral Ab aggregation differs in aging APP23
and APPPS1 mice
Two well-described mouse models of cerebral b-amyloidosis were
used, APP23 [16] and APPPS1 [17]. To determine the approximate
average lifespan of each model, 15-month-old male animals of each
mouse strain were closely monitored and further aged until fulfilling
the euthanasia criteria (“end stage”; see Materials and Methods).
Results revealed a median lifespan of 28.6 months for male APP23
mice and 22.1 months for male APPPS1 mice (Fig 1A). Based on
this observation, age groups were determined a priori, and brains
were collected from 2-, 6-, 12-, 18-, 25-month-old and end-stage
mice for the APP23 line, and from 1.2-, 3-, 6-, 12-, 18-month-old and
end-stage mice for the APPPS1 line.
Immunohistochemical staining revealed a progressive increase of
Ab deposition for both mouse lines with advancing age. In APP23
mice, Ab deposition was rarely seen at 6 months of age, but was
conspicuous at 12 months, particularly in the frontal cortex
(Fig 1B). At 18 months of age and beyond, parenchymal Ab
deposits occurred in most forebrain regions, and cerebral b-amyloid
angiopathy (CAA) also was present. In APPPS1 mice, the onset of
Ab deposition was much earlier than in APP23 mice (Fig 1C). While
1.2-month-old APPPS1 mice did not show Ab deposition, robust
deposition was present in most brain regions at 3 months of age,
with the frontal region again being most affected. The number of Ab
plaques continued to increase thereafter (Fig 1C). CAA was not a
prominent feature in the APPPS1 mouse model.
Consistent with the immunohistochemical appearance of the Ab
lesions, human sequence Ab40 and Ab42 in brain homogenates
from APP23 and APPPS1 mice increased with advancing age (Fig 1D
and E). While the increases at early stages appeared to be exponen-
tial, at later stages, the increase was 1.5- to twofold in APP23 mice
(from 18 to 25 months to end stage) and 1.1- to 1.4-fold in APPPS1
mice (from 12 to 18 months to end stage). At end stage, Ab42 levels
were 1.8-fold higher in the APPPS1 mice compared to APPP23 mice
(33,000 vs. 18,000 pmol/g wet brain weight); in contrast, Ab40
levels at end stage were 10-fold higher in APP23 mice compared to
APPPS1 mice (120,000 vs. 12,000 pmol/g wet brain weight).
Of note, the Ab42/Ab40 ratio in both models sharply increased
around the onset of Ab deposition (12 months in APP23 mice and
3 months in APPPS1 mice) and declined thereafter (Fig 1D and E).
Overall, the Ab42/Ab40 ratios were higher in the APPPS1 model,
consistent with the expression of L166P-mutated human PS1, which
is known to favor cleavage at the Ab42 site [17].
The b-amyloid-inducing activity in brain extracts reaches a
plateau with aging
We have previously found that both membrane-bound pellet and
soluble fractions of b-amyloid-laden brains are seeding active
[18,19]. In particular, the PBS-soluble 100,000 g fraction was highly
active but represented only a small fraction of the entire seeding
activity [18]. Therefore, in this study, the 3,000 g supernatant (total
without large debris) has been used to compare the (total)
b-amyloid-inducing activity of brain extracts among the mouse lines
and age groups.
To this end, an endpoint titration bioassay was applied (see
Materials and Methods). Extracts from APP23 and APPPS1 mice
were serially diluted up to 10!4 in PBS, and each dilution was
stereotactically injected into the hippocampus of 3- to 4-month-old
APP23 mice. Host mice were analyzed 6 months later by Ab
immunohistochemistry, and the number of positively seeded
mice was assessed for each dilution, age group, and mouse line
(Fig 2A–C).
Brain extracts (undiluted) from 2- and 6-month-old male APP23
donor mice, which lacked immunohistochemically detectable Ab
deposition (see Fig 1), failed to induce Ab deposition in host mice
during the 6-month incubation period employed in this assay. In
contrast, brain extracts prepared from APP23 mice at 12 months or
older efficiently induced cerebral b-amyloidosis in the host mice
(Fig 2B). Similarly, brain extracts (undiluted) from 1.2-month-old
APPPS1 mice failed to induce Ab deposition, while extracts from
APPPS1 mice at 3 months and older were robustly seeding active
(Fig 2C). Notably, the Ab deposition induced with the APP23
extracts was morphologically different from the Ab deposition
induced with the APPPS1 extracts, and this was independent of the
age of the donors (Fig 2B and C). This observation is reminiscent of
the previously reported strain-like transmission of Ab morphotypes
[20].
To determine the seeding activity of the various brain extracts
quantitatively, the number of host mice with induced Ab deposition
in the hippocampus was assessed for each extract and dilution
(Fig 2D and E). Subsequently, the seeding dilution (SD50) at which
half of the inoculated animals showed seeded hippocampal Ab
deposition was calculated using the Reed and Muench method [21].
The SD50 increased from 10
0.85 at 12 months to 103 at the end stage
in the APP23 line (Fig 2F and G). For the APPPS1 line, the titers
were similar, but were reached at a younger age, that is, the SD50
increased from 101.63 at 3 months of age to 102.57 at the end stage
(Fig 2F and G). Surprisingly, from 18 months of age in APP23 mice
and from 6 months of age in APPPS1 mice, the SD50 reached a
plateau and did not increase further. To validate the Reed and
Muench method, the Spearman–Ka¨rber method [22,23] was alterna-
tively applied, and this yielded similar results (Table 1). Finally,
logarithmic curve-fitting using a built-in method of PrismTM (Equa-
tion Log agonist vs. response with or without Hill Slope correction)
was used to calculate statistical differences (Table 1).
The specific b-amyloid-inducing activity peaks during the earliest
stages of Ab deposition
The b-amyloid-inducing activity of brain extracts is dependent on
the presence of Ab [11,24]. Thus, the specific SD50 was calculated
(Fig 2F and G; Table 2), that is, SD50 normalized to the Ab
concentration (monomeric Ab equivalent). Remarkably, in both
mouse models, the highest specific SD50 occurred at the onset of
Ab plaque deposition, independent of whether it is normalized to
the concentration of Ab40 or Ab42 (not shown), or total Ab (i.e.,
Ab40 + Ab42; Fig 2F and G; Table 2). Notably, this time point also
coincides with a temporary increase in the brain Ab42/Ab40 ratio
in both models (Fig 1D and E). Except for the extracts from young
donor mice that failed to induce seeding in our assay, the specific
SD50 was higher in APPPS1 mouse brains than in APP23 mouse
brains (Fig 2F and G). Moreover, the specific SD50 in APPPS1 mice
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Figure 1. Age-related changes in cerebral Ab load in APP23 and APPPS1 tg mice.
A Survival curves of APP23 (n = 19; males) and APPPS1 (n = 29; males) mice were generated by following cohorts of both strains from 15 months of age until the
mice were sacrificed due to deteriorating health. Median survival time for APP23 mice was 28.6 months, and for APPPS1 mice 22.1 months (Chi square = 29.63,
df = 1; P < 0.001).
B, C Ab immunostaining (black) combined with Congo red staining (red) shows Ab deposits in the neocortex (upper row) and hippocampus (lower row) of male APP23
mice (B) and male APPPS1 mice (C) at different ages. End stage was defined as the point at which mice had to be terminated due to poor health (n = 5–9 male
mice/group; representative images from each time point are shown). Scale bars: 200 lm.
D, E Ab40, Ab42, and Ab42/Ab40 ratio in total brain homogenates of separate animal cohorts (n = 7–11 male mice per group) for APP23 mice (F5,56 = 339.7, F5,56 = 332.8,
F5,56 = 145.5, respectively) (D) and APPPS1 mice (F5,41 = 168.4, F5,41 = 257.2, F5,41 = 182.4, respectively) (E) measured by immunoassays (mean ! SEM); ANOVA
followed by post hoc Bonferroni test: *P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant.
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Figure 2. Seeding activity of brain extracts from APP23 and APPPS1 tg mice increases with donor age and plateaus in late stages.
A–C Brain extracts from APP23 (B) and APPPS1 (C) mice at different ages were injected into the hippocampus of young, pre-depositing 3- to 4-month-old male APP23
host mice. Brains were immunohistochemically analyzed for Ab deposition 6 months later. Ab immunostaining combined with Congo red staining is shown. Note
the more diffuse and filamentous Ab deposition induced with the APP23 extracts in contrast to the punctate and compact Ab deposition induced with the APPPS1
extracts. Scale bars: 200 lm.
D, E Number of mice with induced Ab deposition at each dilution from the different age groups (n = mainly 3–6/group) of APP23 (D) and APPPS1 (E) brain extracts.
F, G SD50 of APP23 (F) and APPPS1 (G) brain extracts (blue line; Reed-Muench method, see Table 1 for statistical analysis). SD50 (half-maximal seeding dose) was defined
as the log10 of the brain extract dilution at which 50% of the host mice showed induced Ab deposition (see Materials and Methods). The specific seeding activity
(SD50/total Ab; red line) for each extract indicates a peak at early ages in brain extracts from both mouse lines (see Table 2).
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differed by roughly 3 log10 between early and late time points
(Fig 2G; Table 2).
Rationale for directing anti-Ab therapeutics to the earliest stage
of the pathogenic cascade
Despite the importance of Ab aggregation as a trigger of AD patho-
genesis, there is little information on whether the biological activity
of the aggregated peptide changes as the disease evolves. In this
series of studies, we determined the potency of Ab seeds using the
in vivo induction of Ab aggregation as a readout. For this purpose,
we used two distinct APP-tg mouse models with differing rates of
deposition. Although the age at which Ab deposits first appear in
these models is quite different, the emergence of Ab seeds that are
able to induce detectable deposition within the time-frame of our
assay coincides with the earliest ages of deposition in the donor
mouse (note that the exact age of onset is 8–9 months and
1.5 months in male APP23 and APPPS1 mice, respectively, but these
ages were not tested in the current study). Remarkably, at later
stages of life in both models, the correlation of seeding activity with
the Ab load diminishes, as seeding activity reaches a plateau even
though Ab deposition continues to increase as the mice age. Conse-
quently, the highest seeding activity relative to total Ab (the specific
seeding activity) occurs at the inception of Ab deposition, and this
coincides with a peak of the Ab42/Ab40 ratio.
We first followed Ab deposition across the average lifespan of
APP23 and APPPS1 mouse models. Consistent with previous reports
[25–28], we observed a steep increase of both Ab40 and Ab42 levels
beginning at the age of onset of plaque deposition in both mouse
lines. At end stage, total Ab levels (Ab40 + Ab42) were threefold
higher in APP23 mice compared to APPPS1 mice, and this was due
to a massive increase of Ab40 in aged APP23 mice. This was not
only due to insoluble aggregates as post hoc analysis of the
100,000 g soluble fractions from a different study also showed an
age-related increase in both models (not further analyzed here).
Nonetheless, longevity is shorter in APPPS1 mice than in APP23
mice, possibly indicating a minor contribution or protective effect of
Ab40. The shorter lifespan of APPPS1 mice could also be a conse-
quence of the PS1 transgene overexpression.
Although Ab seeds are known to induce cerebral Ab aggregation
in a concentration-dependent manner [29,30], the potency of Ab
seeds, that is, the amount of Ab-containing species needed to induce
Ab deposition, has been difficult to quantify. The latter, however, is
important for current efforts to purify Ab seeding activity. In the
present study, we therefore developed an endpoint titration bioassay
similar to those used to measure prion infectivity [31,32] and more
recently for Ab [33]. We were thus able to establish the dose of Ab
seeds that induces deposition in 50% of the animals (the seeding
dilution or dose 50, or SD50) as a reliable measure of the activity of
Ab seeds. Using this assay, we found that the seeding activity of
PBS-soluble brain extracts initially increases exponentially with age,
but then reaches a plateau in both mouse models. At the plateau
stage, a single APP23 mouse brain contains approximately
1,600,000 seeding units, while an APPPS1 brain contains roughly
600,000 units (based on the assumption of a mouse brain weighing
400 mg). Interestingly, in prion disease, infectious prions in the
brain first increase exponentially, followed by a plateau in prion
titers that governs the onset of clinical disease, suggesting a transi-
tion to the generation of toxic assemblies of the prion protein that
differ from the infectious prion seeds [32]. Whether similarly
distinct species of Ab exist over the course of AD pathogenesis and
whether the earlier plateauing of seeding potency in the APPPS1 line
is responsible for the early death of these mice is not known.
Strikingly, the seeding potency of Ab (specific SD50) in both
mouse models peaks during the earliest stages of Ab deposition.
Moreover, this spike in seeding potency coincides with a transient
increase in the Ab42/Ab40 ratio, which occurs shortly after the
onset of Ab deposition and then decreases as plaques and CAA
proliferate in the brain [27,28]. Therefore, Ab seed potency, the
Ab42/Ab40 ratio, and deposition stage are closely linked, and this is
Table 1. Comparison of SD50 values (log10) calculated with different methods for all age groups of APP23 and APPPS1 brain extracts.
APP23 APPPS1
2
months
6
months
12
months
18
months
25
months End-stage
1.2
months
3
months
6
months
12
months
18
months End-stage
Reed-Muench 0.00 0.00 0.85 2.80 3.00 3.00 0.00 1.63 2.17 2.50 2.50 2.57
Spearman-
Kärber
0.00 0.00 1.23 2.90 3.07 2.81 0.00 1.70 2.10 2.50 2.50 2.63
Curve-fitting 0.00 0.00 1.12 ! 0.00 3.08 ! 0.06 2.99 ! 0.18 2.95 ! 0.16 0.00 1.61 ! 0.38 2.15 ! 0.14 2.55 ! 0.14 2.54 ! 0.43 2.63 ! 0.08
Curve-fitting based on the Reed-Muench method was used for statistical analysis. The SEM is indicated. Two-way ANOVA revealed a significant effect for age
group (F5,184 = 25.88; P < 0.001) but not for genotype (F1,184 = 1.35; P = 0.25). There was a significant interaction of genotype x age group (F5,184 = 3.537;
P < 0.01). N was 5–29 and results from the summed numbers of mice examined in Fig 2D and E. Subsequent post hoc Bonferroni tests revealed that seed titers
plateaued starting at 18 months for APP23, and at 6 months for APPPS1, group comparisons P > 0.05.
Table 2. Specific seeding activity (SD50 per total Ab) contained in injected material from donor mice of different ages.
APP23 APPPS1
2
months
6
months
12
months
18
months
25
months End-stage
1.2
months
3
months
6
months
12
months
18
months End-stage
Total Ab (fmol) 1.67 1.52 6.91 824.87 3075.50 3830.74 3.78 10.11 118.53 296.76 360.38 473.08
SD50/total Ab (0.00) (0.00) 1.03 0.76 0.33 0.26 (0.00) 4.21 1.24 1.07 0.88 0.78
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true in both APP23 and APPPS1 mouse models. The greater potency
of Ab seeds during all stages of deposition in APPPS1 mice corre-
sponds to the higher Ab42/Ab40 ratio (Fig 1) and relatively more
aggregated Ab species (Fig EV1) in APPPS1 mice compared to
APP23 mice. Our results thus support the hypothesis that Ab42-
containing aggregates are particularly effective components of
bioactive Ab seeds.
The peak in specific seeding activity of Ab early during deposi-
tion may be due to the predominance of relatively small aggregates
at this time, which results in a large number of molecular seeding
surfaces relative to the number of total Ab molecules present. With
increasing aggregation (and increasing total Ab), an increasing frac-
tion of molecular seeding surfaces may be buried within the aggre-
gates and unable to template other Ab molecules. However, it is
also possible that the evolving potency of Ab seeds results from
features of the assemblies that change as the disease process
advances in the brain, a possibility also in line with the coincident
spikes in seeding potency and the Ab42/Ab40 ratio. Although the
preparation of our injectable material (3,000 g) was relatively
gentle, we cannot exclude effects on the aggregation state of the
seeds or their interaction with other proteins that might modulate
the seeding activity.
Implications
Our findings in transgenic mouse models indicate that Ab seeds are
most potent in the early stages of Ab deposition and that this spike
in specific seeding activity is associated with a transient increase in
the Ab42/Ab40 ratio. Thereafter, both Ab levels and the total seed-
ing activity increase rapidly, followed by a leveling-off of the seed-
ing activity even as total Ab levels continue to climb. Our results
demonstrate that the pathobiology of Ab changes as the disease
process evolves, at least with respect to the seeding capacity of aber-
rant Ab. The particular potency of Ab seeds in the initial stages
underscores the importance of therapeutically targeting Ab deposi-
tion in the brain before it becomes detectable by PET imaging or
CSF biomarker analysis. In this light, more sensitive biomarkers are
needed that will enable earlier or even predictive identification of
the AD pathogenic process. Therapeutically, compounds that
prevent the formation or activity of Ab seeds hold particular
promise for the prevention and treatment of AD.
Materials and Methods
Mice
All animal experiments were conducted in compliance with proto-
cols approved by the local Animal Care and Use Committee. APP23
mice overexpress KM670/671NL-mutated human APP under the
control of a neuronal Thy1 promoter. The mice were generated on a
B6D2 background [16], but they have been backcrossed to C57BL/
6J for more than 25 generations. APPPS1 mice express the same
mutant form of APP together with L166P-mutated presenilin-1,
again under the control of the neuron-specific Thy1 promoter
element, and were generated and maintained on a C57BL/6J genetic
background [17]. Male and female APP23 mice differ in the age at
which endogenous amyloid deposition begins [27]. Therefore, to
reduce variation in age-related deposition, male APP23 and, consis-
tently, male APPPS1 mice were used. All donor mice were group-
housed under specific pathogen-free conditions (APP23 in Basel,
Novartis; APPPS1 in Tu¨bingen, Hertie Institute for Clinical Brain
Research). Mice were inspected regularly for health issues. Mice
were euthanized when they reached a pre-specified age or in the
event that they were deemed to be in intractable distress based on
an independent assessment by the animal caretaker according to
AVMA Guidelines (https://www.avma.org/KB/Policies/Docume
nts/euthanasia.pdf). The latter criterion was used to determine the
end-stage time point that defined the median lifespan of each of the
mouse lines. Mice were sacrificed by cervical dislocation under
isoflurane anesthesia. Brains were removed from sacrificed mice,
immediately frozen using dry ice, and stored at !80°C until use for
either histological staining or brain tissue homogenate preparation.
All experimental procedures with the mice were carried out in
accordance with the veterinary office regulations of Baden-Wuert-
temberg (Germany) and approved by the local Animal Care and Use
Committees.
Ab immunohistochemical analysis of APP23 and APPPS1 mice
Brains (hemispheres) were cut sagittally (15 lm thickness) with a
cryostat, and a representative set of sections (every 20th section)
was stained immunohistochemically with an in-house polyclonal
antibody directed against Ab and the Vectastain Elite ABC kit (Vec-
tor Laboratories, Burlingame, CA) as previously described [12].
Sections were then co-stained with Congo red according to standard
protocols. Representative images are shown in Fig 1 for each time
point and genotype (n = 5–9 male mice were used per age group).
Preparation of brain tissue homogenates
Brains from a separate cohort of male mice (n = 7–11 per age
group) were homogenized in sterile PBS (10%, w/v) at 4°C
(2 × 10 s at 5,500 rpm, each round separated by a 10 s pause) using
a Precellys 24 Dual homogenizer (Bertin, Montigny-le-Bretonneux,
France; 7 ml lysing tubes with 2.8 mm ceramic beads). Samples
were stored at !80°C. Brain homogenates were either kept for
further quantitative Ab analysis or used for intracerebral injections.
Quantification of Ab by electrochemiluminescence-linked
immunoassay
Ab peptides (Ab40 and Ab42) in brain homogenates were quantified
with an electrochemiluminescence-linked immunoassay using the
MSD! 96-well Human (6E10) Ab Triplex Assay (MesoScale Discov-
ery); 96-well plates that had been pre-spotted with capture antibod-
ies against Ab40 and Ab42 were blocked for 1 h with 1% bovine
serum albumin in Tris buffer and washed three times with 1× Tris
buffer. Samples were treated with formic acid (final concentration:
70%) (Sigma), sonicated for 30 s on ice, and centrifuged at
25,000 × g for 1 h at 4°C. Supernatants were equilibrated in neutral-
ization buffer (1 M Tris base, 0.5 M Na2HPO4, 0.05% NaN3) and
diluted up to 1:1,000 (depending on Ab load, to stay within the
linear range of the assay) in 1% BSA. Samples were then co-
incubated with the SULFO-TAG 6E10 detection antibody solution on
the plate for 2 h. After washing, MSD Read Buffer T was added and
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the plate was read immediately on a Sector Imager 6000. Data analy-
sis used MSD DISCOVERY WORKBENCH software 2.0.
Intracerebral injections and serial dilution of brain extracts
For intracerebral injections, brain homogenates were centrifuged at
3,000 × g for 5 min at 4°C and the supernatant collected (hereafter
referred as “brain extract”). In order to reduce individual mouse
variability, for each age group, brain extracts from all the mice
within an age group were pooled (n = 8–10 per group; see above)
and then serially diluted up to 10!4 fold in sterile PBS. Host mice
were 3- to 4-month-old male APP23 mice (n = mainly 3–6 per
group). The mice were anaesthetized with a mixture of ketamine
(110 mg/kg body weight) and xylazine (20 mg/kg body weight) in
saline; 2.5 ll of each brain extract or dilution thereof were bilater-
ally delivered to the hippocampus (AP: !2.5 mm, L: +/! 2.0 mm,
DV: !1.8 mm) with a Hamilton syringe. Injections were performed
at 1.25 ll/min, and the needle was kept in place for an additional
2.5 min before being slowly withdrawn. The surgical area was
cleaned with sterile saline, the incision was sutured, and the mice
were monitored until recovery from anesthesia.
Endpoint titration assay to estimate SD50
After 6 months of incubation, mice inoculated with brain extracts
were deeply anaesthetized with ketamine (250 mg/kg)/xylazine
(25 mg/kg) and sacrificed by transcardial perfusion with ice-cold
PBS. Brains were immersion-fixed for 48 h in 4% paraformalde-
hyde in PBS and then cryoprotected in 30% sucrose in PBS for an
additional 48 h. Fixed brains were serially cut into 25-lm-thick
coronal sections on a freezing-sliding microtome (Microm, Thermo
Scientific) and collected in a 12-well plate containing cryoprotec-
tant (35% ethylene glycol, 25% glycerol in PBS) for storage at
!20°C. Sections from a single well (containing every 12th section)
were then stained immunohistochemically with a polyclonal anti-
body directed against Ab and co-stained with Congo red according
to standard protocols (see Ab immunohistochemical analysis
above).
To quantify the seeding activity of extracts from donors at dif-
ferent ages, we calculated the half-maximal Ab seeding titers (SD50)
using titration assays similar to those used in prion infectivity titer
measurements. The classic methods for measuring scrapie prion
infectivity in vivo are the endpoint titration bioassay and the incuba-
tion time interval assay [34–36]. Although the latter is less costly
and time-consuming [36], the absence of reliable and obvious clini-
cal symptoms in APP transgenic mouse models limited its feasibility
for these models. Therefore, we chose the endpoint titration bioas-
say and killed animals after a fixed incubation time.
Positive or negative induction of Ab deposition was rated on the
Ab-immunostained sections throughout the hippocampus for each
animal. Note that endogenous Ab plaques in the hippocampus of
male 9- to 10-month-old APP23 mice are absent [11] or limited to
no more than one plaque per section. Moreover, rare endogenous
Ab plaques can be distinguished from induced Ab deposition,
which reveals the typical induction pattern along the layers in the
dentate gyrus (see Fig 2B and C). Two independent raters
performed the quantification blinded, and their assessments were
100% congruent.
The number of animals that showed induced Ab deposition at
each dilution was determined in order to calculate the Ab seeding
titer. Titers (SD50) were calculated by counting positively seeded
animals vs total animals according to Reed and Muench [21] or the
Spearman–Ka¨rber method [22,23]. Calculation with logarithmic
curve-fitting was based on the numbers of positive vs total animals
as determined with the Reed and Muench method [21] using Equa-
tion Log agonist vs. response with or without Hill Slope correction,
as provided by GraphPad PrismTM version 5.
Dot blot assay
For further characterization, “brain extracts” of a given age group
were pooled, IgG-depleted using Sheep Anti-Mouse Dynabeads (Life
Technologies, 11201D) and total protein determined by BCA
assay (Thermo). Samples were serially diluted in PBS containing
protease- and phosphatase-inhibitors (Thermo) at the following
dilutions: 10!1, 10!2 and 10!3. Samples were spotted on nitrocellu-
lose membranes so that 3 lg total protein was contained in the
undiluted (100) area. An aged non-transgenic mouse (29 months
old; wild type) seeding extract was included in addition to synthetic
Ab samples. Synthetic Ab1–40 and Ab1–42 (Bachem, H-1194 and H-
8146, respectively) were fibrillized at 37°C (100 lM Ab, 10 mM
HCl, 150 mM NaCl) for 5 days without shaking and 5 ng of each
was spotted on membranes, in addition to a monomeric Ab1–40
control (5 ng). Blotting and probing with OC (Millipore, AB2286)
were performed as previously described [37]. Briefly, membranes
were rehydrated in Tris–glycine (25–192 mM) buffer containing
20% MetOH, then incubated in hydrogen peroxide (0.3% in PBS)
for 15 min. After washing, membranes were blocked in skim milk
(10% in PBS-0.05% Tween -> PBS-T) for 60 min and probed with
OC overnight at 4°C (1:10,000, PBS-T with 5% BSA). Membranes
were washed with PBS-T and incubated in donkey anti-rabbit-HRP
secondary (1:30,000; Jackson ImmunoResearch Laboratories, 711-
035-152) for 60 min, then washed (PBS-T) prior to developing with
SuperSignalTM West Dura Extended Duration Substrate (Thermo)
and exposed on Hyperfilm (Amersham). Staining with 6E10 (BioLe-
gend, 803017) and N25 (gift of M. Mercken) [38] was done in paral-
lel, with membranes being heated in PBS after rehydration (95°C for
5 min) and blocked in skim milk (5% in PBS-T) for 60 min.
Membranes were incubated in 6E10 (1:5,000 in PBS-T) or N25
(1:5,000 in PBS-T) overnight at 4°C before being washed (PBS-T)
and incubated in goat anti-mouse (1:30,000; Jackson Immuno-
Research Laboratories, 115-035-068) for 60 min. Membranes were
developed in the same way as for OC. Control blots without addition
of primary antibodies were also done in parallel with both anti-
rabbit and anti-mouse secondaries.
Statistical analysis
GraphPad PrismTM version 5 was used for all statistical analyses.
Expanded View for this article is available online.
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	 84    
Expanded View Figures
Figure EV1. Age-dependent increase of fibrillar Ab species in seeding extracts for both transgenic mouse models.
Pooled seeding extracts used for in vivo inoculations were spotted on nitrocellulose membranes and probed with antibodies against fibrillar Ab epitopes (OC) or monomeric
Ab epitopes at amino acids (aa) 3–8 (6E10) or aa 1–5 (N25). An aged wild-type (WT) control brain extract was used at the same total protein concentration as the
transgenic samples (i.e., 3 lg total protein in 100) in addition to 5 ng of each monomeric Ab1–40, fibrillar Ab1–40, and fibrillar Ab1–42. Presented is a representative blot
performed in duplicate. M = monomer, F = fibril, ES = end stage.
EMBO reports ª 2017 The Authors
EMBO reports Ab seeding early in disease Lan Ye et al
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Abstract 
 
The seminal event in Alzheimer’s disease pathogenesis is the aggregation and deposition of 
the β-amyloid (Aβ) peptide. Aβ aggregation produces a diverse population of different Aβ 
assemblies in the brain, ranging from monomers to large fibrillar aggregates. A detailed 
analysis of the biochemical or biological properties of aggregated Aβ species is lacking 
because of the inherent difficulties to isolate these species in their native form. Here, an 
agarose fractionation method is presented that separates brain-derived Aβ assemblies based 
on size. The agarose fractions are then enzymatically digested to liberate the native Aβ 
assemblies that can then be tested for their biological activities. Indeed using this novel 
approach we could show that brain-derived Aβ assemblies displayed migration patterns that 
were different from synthetic Aβ aggregates. Additionally, we could show that the quaternary 
structure and biological in vivo seeding activity of brain-derived Aβ aggregates was 
preserved after fractionation and liberation of the Aβ assemblies. Finally, 
immunoprecipitation of the fractionated native Aβ assemblies allowed for the screening of 
Aβ antibodies for their recognition of various assemblies. This method for enriching seeding 
active subpopulations of Aβ has enormous potential for investigating the correlation between 
structure and pathobiology but also for the screening and development of novel therapeutics. 
Moreover, the same method can be exploited for other proteopathic protein assemblies such 
as tau and α-synuclein. 
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Introduction 
 
The progression of Alzheimer’s disease (AD) is currently an unstoppable neurodegenerative 
process that devastates many elderly people. The β-amyloid (Aβ) peptide is the principle 
component of senile plaques and additionally is hypothesized as the initiating factor for 
disease (Masters et al. 1985; Wong et al. 1985; Selkoe and Hardy 2016). Given its central 
role in disease, many attempts at slowing neurodegeneration therapeutically have targeted the 
Aβ peptide (Karran et al. 2011). 
 
It is well known that along the aggregation pathway of Aβ there exists many different 
species, from small monomers and oligomers to larger protofibrils and fibrils (Haass and 
Selkoe 2007; Jucker and Walker 2013). A central debate within the AD field is what role 
each distinct Aβ species has on the disease process. A number of studies have shown the 
soluble dimers and oligomers can modulate synapses (Walsh et al. 2002; Lesne et al. 2006; 
Klyubin et al. 2008; Shankar et al. 2008; Amar et al. 2017). It has been proposed that there 
are even on-pathway and off-pathway oligomers generated in the fibrillization cascade (Liu 
et al. 2015). These diverse multimeric species clearly modulate the brain environment, 
however, it is important to consider the source of Aβ being used for in vivo characterization. 
It has been shown that in vitro Aβ does not replicate certain aspects of in vivo samples, such 
as the ability to seed Aβ deposition in APP transgenic hosts (Meyer-Luehmann et al. 2006; 
Novotny et al. 2016). Additionally, there is evidence that the potency of Aβ changes over the 
course of amyloidosis and this further emphasizes the need to carefully select in vivo Aβ 
species for further characterization (Ye et al. 2017). Thus a method for investigating different 
structures of in vivo Aβ is of need to enhance the understanding of disease. 
 
This study aimed at developing a method for the enrichment of Aβ species of different sizes 
with an agarose gel fractionation system. We demonstrate that Aβ species can be separated 
by size while retaining quaternary structural features and biological seeding properties. The 
application of this to an array of downstream applications such as therapeutic screening and 
novel immunotherapy generation is highly promising. 
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Methods 
 
Mouse brain extracts 
Transgenic mice overexpressing the human APP protein with the Swedish mutation 
(KM670/671NL) under control of the Thy1 promoter on a C57/Bl6 background were used 
throughout the study (Sturchler-Pierrat et al. 1997). Mice were deeply anesthetized with 
ketamine/xylazine (250/25 mg/kg) and sacrificed by cervical dislocation. After removal of 
the brain stem and cerebellum, mouse brains were homogenized (10%) with the Precellys 
system in PBS (2x20 sec, 5500 rpm; Precellys24 Homogenizer, Bertin Instruments). 
Homogenates were centrifuged for 5 min at 3000 g and the supernatants were collected and 
stored at -80°C until further analysis. Pooled brain extracts from Ye et al. (2017) were used 
for the characterization of different ages (Fig 1C-E). Extracts used in later analysis were 
prepared from 28 mo old mice (Fig 2). 
 
In vitro Aβ samples 
Monomeric Aβ was prepared using synthetic Aβ1-40 (Bachem) and was dissolved in DMSO 
and stored at -80°C prior to analysis. For preparation of oligomers, a protocol for Aβ derived 
diffusible ligands (ADDLs) was followed using Aβ1-42 (Ryan et al. 2010). Briefly, Aβ1-42 
(Bachem) was dissolved in HFIP and, after evaporation, resuspended in DMSO to a 
concentration of 5 mM then further diluted in PBS-SDS (0.05%) to 100 μM and incubated at 
4°C for 24 h. Samples were then diluted to 11 μM and incubated for 2 weeks at 4°C. Fibrils 
were prepared from Aβ1-42 by incubating at 37°C for 24 h at a concentration of 100 μM (10 
mM HCl, 150 mM NaCl). 
 
Semi-denaturing agarose fractionation 
The methodology for resolving larger aggregates of Aβ was adapted from a previous study 
(Bagriantsev et al. 2006). Samples were mixed with loading buffer (50 mM Tris pH 6.8, 2% 
SDS, 5% glycerol) at RT for 7 min then electrophoresed on a 2% low melting point (LMP) 
agarose gel (20 mM Tris, 200 mM Glycine, 0.1% SDS) at 25 V for 45 min in Tris-Glycine 
buffer (20 mM-200 mM) and subsequently cut into 1-centimeter fractions. 
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For direct analysis of Aβ, gel pieces were then melted in denaturing sample buffer (62.5 mM 
Tris pH 6.8, 8.3% glycerol, 2% SDS, 100 mM DTT) and loaded on a NuPAGE 4-12% Bis-
Tris gel, electrophoresed in NuPAGE MES buffer (Thermo Scientific) then transferred to a 
nitrocellulose membrane. Membranes were probed with 6E10 (1:5000, Covance) and Goat 
Anti-Mouse HRP (1:30000, Jackson Labratories), developed with Super Signal West Dura 
Extended Duration substrate (Thermo Scientific) and the monomeric Aβ signal was 
quantified by densitometry (ImageJ, NIH) from autoradiography films (Amersham Hyperfilm 
ECL). Results are representative of two technical replicates. 
 
Gel Fraction Digestion and Immunoprecipitation 
Agarose gel fractions were equilibrated in buffer (50 mM Bis-Tris pH 6.5, 1 mM EDTA), 
diluted to a 1% agarose concentration and then melted at 65°C for 10 min, cooled to 42°C 
and digested for 60 min with agarase (Sigma-Aldrich, A6306). Liquid samples were then 
aliquoted and stored at -80°C prior to sample analysis. Samples were thawed on ice and 
incubated on a rotator overnight at 4°C with Protein G Dynabeads (Thermo Scientific) 
coupled to different antibodies (4.8 μg IgG / 20 μl beads). Aβ antibodies with a linear epitope 
including N25 (gift from Janssen Pharmaceuticals) and 4G8 (Covance) were used in addition 
to the conformation-specific amyloid antibody mOC31 (Hatami et al. 2014) and control anti-
wheat germ antibody (gift from Biogen). Beads were washed with PBS-Tween20 (0.05%) 
prior to the eluted antigen being recovered with heating at 70°C for 10min in LDS Sample 
Buffer (Thermo Scientific). Denatured eluate was then electrophoresed on NuPAGE 4-12% 
Bis-Tris gels in NuPAGE MES buffer (Thermo Scientific), transferred to nitrocellulose and 
probed with 6E10 (1:5000, Covance) and Goat Anti-Mouse HRP (1:30000, Jackson 
Labratories). Signals were captured with autoradiography film (Amersham Hyperfilm ECL). 
Results are representative of three technical replicates. 
 
Mouse Injections 
Pre-depositing male APP23 mice (4 mo) were anesthetized with ketamine/xylazine (100/10 
mg/kg) and 2.5μL of fraction 2 from an APP23 end-stage (ES, n=7) or aged WT (n=3) was 
infused at a rate of 1.25 μL/min into both hippocampi (bregma: -2.5 mm anterior/posterior; 
+/- 2.0 mm lateral; -1.8 mm dorsal/ventral). Mice were monitored closely until regaining 
consciousness and weighed weekly until the completion of the experiment. After six months, 
mice were deeply anaesthesized with ketamine/xylazine (250/25 mg/kg) and perfused with 
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ice-cold PBS. Brains were immersion fixed in paraformaldehyde (4%) for 48 h, incubated in 
30% sucrose for another 48 h, then snap frozen in methyl butane. Brains were sectioned on a 
freeze-sliding microtome (25 μm, Microme Leica) and stained with a polyclonal Aβ antibody 
using the Vectastain ABC system (Rasmussen et al. 2017). 
 
Results 
 
The resolution of larger aggregates was achieved using Invitrogen cassettes (1.5 mm) and a 
low-melting point (LMP; 2%) semi-denaturing agarose gel. The running behavior was 
controlled using a stained protein ladder (SeeBlue Plus 2, Invitrogen) as a reference for 
migration distance (Fig. 1A). Gels were then cut into seven 1 cm fractions with the first 
fraction containing only the bottom of wells (0.5 cm) to analyze Aβ species too large to enter 
the agarose gel (Fig. 1A). To confirm the running behavior of different in vitro Aβ 
preparations, monomers, oligomers and fibrils were run on the semi-denaturing gel and 
fractions were collected and analyzed by complete denaturing PAGE (Fig. 1B). Aβ was 
found only in the smaller fractions for monomers, while oligomers harboured Aβ in 
moderately sized fractions and fibril samples had Aβ populating all fractions (Fig. 1B). Next, 
the migration behavior of in vivo Aβ from APP23 mouse brain extracts was investigated (Fig 
1C-E). In all ages of mouse extract investigated, there was Aβ present in every fraction, but 
predominantly in the first and last fraction (Fig 1D-E). The pattern of Aβ distribution 
between ages was largely similar (Fig. 1E). 
 
The agarose fractionation methodology was then expanded to produce a liquid suspension 
from LMP agar fractions using enzymatic agarase digestion. Aged brain extracts were first 
separated by agarose electrophoresis and cut into fractions as above but then digested with 
agarase. After digestion, immunoprecipitation was performed on different liquid fractions 
with different Aβ antibodies coupled to magnetic beads (Fig 2A). Similar to the distribution 
of Aβ after direct analysis with melting (Fig 1D), antibodies with a linear epitope (N25 and 
4G8) recognized Aβ in almost all fractions with a similar pattern (Fig. 2A). However, the 
aggregate-specific mOC31 antibody (Hatami et al. 2014) only recognized Aβ in the high 
molecular weight fractions (Fig 2A). A mock-labeled control revealed a weak signal in the 
high molecular weight fractions (Fig 2A). 
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To further test the nature of the liberated high molecular weight structures of Aβ, the second 
agarose fraction was injected into the hippocampus of pre-depositing APP23 mice (Fig 2B). 
After six months of incubation, mice were sacrificed and analyzed for Aβ deposition 
histologically. Only mice injected with fraction two from the APP23 ES sample had 
detectable seeded Aβ deposition, while aged WT injected animals lacked this typical seeding 
pattern (Fig 2B). 
 
Discussion 
 
The investigation of subpopulations of Aβ is crucial to better understand its overall role in the 
progression of AD. The data presented outlines a novel method for separating native Aβ 
assemblies based on size, especially the high molecular weight complexes. Crucially, the size 
fractions displayed evidence of a preserved quaternary structure, enabling biochemical 
studies of Aβ composition and biological seeding activity to determine how these fractions 
are different on multiple levels (Fig 2). 
 
The comparison of in vitro fibrillized Aβ to in vivo material revealed an interesting finding in 
terms of the distribution of Aβ (Fig 1). All in vivo samples had a peak in Aβ abundance in the 
highest and lowest molecular weight fractions to suggest a predominance of very large order 
aggregates and monomers (Fig 1D). The excess of monomers can be explained by 
physiological production of Aβ in the APP23 transgenic mouse brain and the higher order 
structures are likely the result of the advanced aggregation state achieved with age and the 
scaffolding supplied by the brain (Sturchler-Pierrat et al. 1997). The in vitro fibrils failed to 
achieve an excess of these large structures (Fig 1B). It is tempting to suggest that the failure 
of in vitro fibrils to act as potent seeds may be due to this discrepancy (Meyer-Luehmann et 
al. 2006; Novotny et al. 2016). 
 
The liberation of Aβ from agarose fractions was crucial for determining whether the peptide 
features were preserved during separation. The relative distribution of Aβ through fractions 
was confirmed with linear-epitope antibodies while the general lack of Aβ signal after control 
pull-down confirmed the specificity of antibodies. The reactivity of the aggregate-specific 
mOC31 antibody only in high molecular weight fractions is strong evidence that Aβ retains 
an aggregated form throughout the fractionation procedure (Hatami et al. 2014). It is worth 
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noting that the mOC31 antibody preferentially stains vascular deposits of Aβ (cerebral 
amyloid angiopathy, CAA) in histological stains as opposed to parenchymal plaques (Hatami 
et al. 2014). It is unclear whether the high molecular weight fractions in this procedure 
contain Aβ derived from CAA exclusively but analysis of another cerebral β-amyloidosis 
model without CAA could clarify this. 
 
The confirmation that Aβ contained in higher molecular weight fractions is capable of 
inducing deposition in vivo confirms that further characterization of samples produced by this 
method is valid. It has shown that highly potent seeds exist in soluble brain extracts (Langer 
et al. 2011; Fritschi et al. 2014). Further analysis of these soluble Aβ species with agarose 
fractionation could determine whether a certain Aβ size is responsible for this increased 
potency. It will be important for such future studies to use a seeding activity bioassay to 
accurately determine the potency of different fractions (Ye et al. 2017). Additionally, it will 
be interesting to investigate a diverse set of biological samples using agarose fractionation, 
from different transgenic mouse lines with various ages to human AD samples. Delineating 
the size of the most potent seeds from transgenic mouse models and humans samples would 
be invaluable to understanding the onset of Aβ pathology. 
 
Previous research has suggested that different subtypes of AD contain Aβ with varying 
biochemical and biological characteristics (Lu et al. 2013; Watts et al. 2014; Cohen et al. 
2015; Qiang et al. 2017; Rasmussen et al. 2017). By applying agarose fractionation, it would 
be possible to determine whether these differences in Aβ are present throughout the entire 
population of aggregates or within a single size class. This information could then be used to 
develop therapeutics directed against subspecies of Aβ with the most potent seeding activity. 
Generating a novel therapeutic based on in vivo derived Aβ with a defined biological activity 
would be invaluable. Detailed structural analysis of Aβ contained within different fractions 
can also be used to gain insight into the relation between structure and biological properties 
of in vivo species. The pairing of structural information and amyloid binding dyes with some 
therapeutic potential, like polythiophenes, has been employed for prion diseases and such a 
guide could be applied for Aβ (Herrmann et al. 2015; Schütz et al. 2017) 
 
The composition of the total Aβ population within different biological samples has not been 
well studied. Further investigation of in vivo Aβ subpopulations using agarose fractionation 
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will lead to a more detailed understanding of the link between biochemistry and structure to 
biological properties such as seeding. Additionally, the simplicity of this system could easily 
be adapted to other amyloid proteins associated with disease to gain insight into the 
relationship of size and seeding for various aggregates. Finally, this method can also be used 
for any other brain-derived protein assemblies, in particular proteopathic assemblies 
associated with neurodegenerative disease such as α-synuclein and tau. 
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Figure 1. Agarose gel fractionation is able to separate different subpopulations of Aβ. (A) 
Depiction of a cassette used for semi-denaturing agarose gel electrophoresis with the 
different fractions represented by red dashed lines (Fraction 1-7; decreasing in molecular 
weight) and the running behavior of protein standards shown on the side. (B-E) Gel fractions 
were melted in complete denaturing sample buffer and ran on complete denaturing NuPAGE 
4-12% Bis-Tris gels (PAGE) to resolve proteins contained within the fractions. (B) In vitro 
Aβ preparations of monomers, oligomers and fibrils display expected size distributions when 
analyzed with a 6E10 blot. (C) Ponceau S staining of a mouse extract (APP23 End-stage) 
shows the distribution of protein species contained within fractions. (D-E) Pooled seeding 
extracts from different ages of APP23 mice (Ye et al. 2017) were fractionated and ran on 
complete denaturing gels (D) and the monomeric Aβ signal (6E10 blot) was analyzed for the 
different size fractions (E). The majority of Aβ is contained within the first (1) and last (7) 
fractions for all extracts. ES=End-stage; MW=molecular weight. 
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Figure 2. Agarose gel fractions can be digested and used for subsequent analysis showing a 
preservation of quaternary structure and biological activity. (A) Gel fractions were melted 
and enzymatically digested with agarase then Aβ was immuno-precipitated with different 
antibodies (Protein G Dynabeads). A control antibody (anti-wheat germ) showed slight 
reactivity with the first fraction (high molecular weight), while N25 (amino acids 1-8) and 
4G8 (amino acids 18-22) pull down Aβ from both large and small molecular weight 
fractions. The fibril-specific antibody mOC31 (Hatami et al. 2014) only showed reactivity 
with larger Aβ species (Fractions 1-3) to suggest a preservation of quaternary structure. (B) 
As a proof-of-concept, fraction 2 from both APP23 ES and an age matched WT extract were 
stereotactically injected (bilateral intra-hippocampus) into pre-depositing male APP23 mice 
and left to incubate for 6 months. Mice injected with fraction 2 from APP23 mice showed Aβ 
deposition within the hippocampus (blue=polyclonal Aβ antibody) but the corresponding WT 
controls did not, demonstrating retention of biological seeding activity. Scale bar=200μm. 
ES=End-stage; MW=molecular weight. 
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4. Appendix 
4.1 Abbreviations 
Aβ; Aβ40; Aβ42 β-amyloid; 40 aa variant; 42 aa variant 
Aη η-amyloid 
aa amino acid 
AD; fAD; sAD Alzheimer’s disease; familial variant; sporadic variant 
ADAM10 a disintegrin and metalloproteinase domain containing protein 10 
ADDL amyloid derived diffusible ligands 
AICD APP intracellular domain 
ApoE; ApoE4 apolipoprotein E; ApoE variant 4 
APP; sAPP amyloid precursor protein; soluble fragment of APP 
ASA amyloid seeding assay 
BACE1/2 β-site APP cleaving enzyme 1/2 
BSE bovine spongiform encephalopathy 
C83; C99 C-terminal fragment 83; C-terminal fragment 99 
CAA cerebral amyloid angiopathy 
CJD; iCJD; sCJD; vCJD Creutzfeldt-Jakob disease; iatrogenic; sporadic; variant 
Cryo-EM electron cryomicroscopy 
CSF cerebrospinal fluid 
GWAS genome wide association study 
h-FTAA heptamer-formylthiophene acetic acid 
LCO luminescent conjugated oligothiophenes 
LD50 lethal dose 50 
LDL; vLDL low-density lipoprotein; very-low-density lipoprotein 
LTP long-term potentiation 
MT5-MMP membrane-type 5 matrix metalloproteinase 
NFT neurofibrillary tangles 
PET positron emission tomography 
PCA posterior cortical atrophy variant of AD 
PiB Pittsburgh compound B 
PMCA protein misfolding cyclic amplification 
PrPC cellular prion protein 
PrPTSE misfolded, disease-associated prion protein 
PSEN1/2 presenilin 1/2 
q-FTAA quadro-formylthiophene acetic acid 
RT-QuIC real-time quaking induced conversion 
	 99 
SEM scanning electron microscopy 
SD50 seeding dose 50 
ssNMR solid-state nuclear magnetic resonance 
ThT thioflavin T 
TME transmissible mink encephalopathy 
TREM2 triggering receptor expressed on myeloid cells 2 
TSE transmissible spongiform encephalopathy 
USD American dollars (currency of the United States of America)  
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